System to monitor and manage patient hydration via plethysmograph variablity index in response to the passive leg raising

Information

  • Patent Grant
  • 12004869
  • Patent Number
    12,004,869
  • Date Filed
    Monday, November 4, 2019
    4 years ago
  • Date Issued
    Tuesday, June 11, 2024
    2 months ago
Abstract
Techniques for predicting fluid responsiveness or fluid unresponsiveness are described. A processor can determine a first prediction of fluid responsiveness or unresponsiveness based on a plethysmograph variability parameter associated with a plethysmograph waveform, and can determine a second prediction of fluid responsiveness or unresponsiveness based on a fluid responsiveness parameter that is associated with an elevation of one or more limbs of the patient. The processor can determine an overall prediction of fluid responsiveness or unresponsiveness based on the first and/or second predictions. Based on overall prediction, the processor can cause administration of fluids and/or termination of administration of fluids.
Description
TECHNICAL FIELD

The present disclosure relates generally to management of patient hydration and assessment of fluids responsiveness.


BACKGROUND

In the management of patients, the decision to administer fluids constitutes a common dilemma for physicians. For example, although a particular patient may be at least partially dehydrated (for example, due to preoperative fasting, sweat loss, urinary excretion, surgical blood loss, fluid shifts or other pathologic processes), the patient may not respond favorably to fluid administration (e.g., intravenous (IV) therapy). That is, the patient may not respond to fluid administration with an increase in stroke volume.


Accordingly, prior to or during fluid administration, it can be desirable to predict whether the patient's stroke volume (or, in some cases, cardiac output) will increase upon the fluid administration. Unfortunately, accurate prediction of an increase in stroke volume or cardiac output upon fluid loading, so-called fluid responsiveness, has proven to be difficult and/or unreliable.


SUMMARY

Techniques for predicting fluid responsiveness or fluid unresponsiveness are described. A processor can determine a first prediction of fluid responsiveness or unresponsiveness based on a plethysmograph variability parameter associated with a plethysmograph waveform, and can determine a second prediction of fluid responsiveness or unresponsiveness based on a fluid responsiveness parameter that is associated with an elevation of one or more limbs of the patient. The processor can determine an overall prediction of fluid responsiveness or unresponsiveness based on the first and/or second predictions. Based on overall prediction, the processor can cause administration of fluids and/or termination of administration of fluids.


In various embodiments, the system can identify a patient's hydration status based on physiological data associated with a patient. For example, in some cases, physiological data can correspond to a plethysmography (pleth) signal detected by a pulse oximetry device. Based on the physiological data, the system can identify a pleth variability parameter that is indicative of the hydration status of the patient, and can determine the hydration status of the patient based on the pleth variability parameter. As a non-limiting example, the pleth variability parameter can include a pleth variability index (PVI). For example, PVI can be obtained noninvasively, automatically, and continuously, and can quantify respiratory induced variations in a perfusion index. PVI can be an indicator of a patient's hydration status (for example, hydrated or dehydrated) and can be presented as a numerical value. In some cases, based on PVI the system can determine a hydration status of the patient.


In some cases, a method of determining fluid responsiveness of a patient includes receiving a sensor signal corresponding to a non-invasive physiological sensor. The non-invasive physiological sensor can be configured to emit light towards a tissue site of a patient, detect the light after it has interacted with the tissue site, and generate the sensor signal based at least in part on the detected light. The method can further include demodulating the sensor signal to generate a plethysmograph waveform including a plurality of pulses corresponding to pulsatile blood flow within the tissue site. The method can further include determining a plethysmograph variability parameter associated with the plethysmograph waveform. The plethysmograph variability parameter can quantify variations in the plethysmograph waveform. The method can further include determining a first prediction of fluid responsiveness based at least in part on the plethysmograph variability parameter. The method can further include determining a second prediction of fluid responsiveness based at least in part on a fluid responsiveness parameter that is associated with an elevation of one or more limbs of the patient. The method can further include outputting an indication of fluid responsiveness of the patient based at least in part on the first prediction of fluid responsiveness and the second prediction of fluid responsiveness.


The method of any of the preceding paragraphs and/or any of the methods disclosed herein may include any combination of the following steps or features described in this paragraph, among other features described herein. The plethysmograph variability parameter can correspond to a value associated with a pleth variability index (PVI). The fluid responsiveness parameter can include a measure of at least one of cardiac output, heart rate, or stroke volume. The method can further include determining a plurality of perfusion parameters based at least in part on the plethysmograph waveform. A particular perfusion parameter of the plurality of perfusion parameters can be determined based at least in part on a peak amplitude and a valley amplitude of a corresponding pulse of the plurality of pulses. Said determining the plethysmograph variability parameter can be based at least in part on a difference between a first and second perfusion parameter of the plurality of perfusion parameters relative to the first perfusion parameter of the plurality of perfusion parameters. The indication of fluid responsiveness of the patient can be an overall prediction of fluid responsiveness of the patient.


The method of any of the preceding paragraphs and/or any of the methods disclosed herein may include any combination of the following steps or features described in this paragraph, among other steps or features described herein. The method can be performed prior to administration fluids to the patient. The method can be performed during administration fluids to the patient. The elevation of the one or more limbs of the patient can be associated with a passive leg raising (PLR) test. The PLR test can be performed prior to administration of fluids to the patient. The PLR test can be performed during administration of fluids to the patient. The method can include performing an action based at least in part on the indication of the fluid responsiveness. The action can include at one of initiating administration of fluids to the patient, terminating the administration of the fluids to the patient, causing a display to display an indication of a recommendation for fluid administration, or causing the display to display an indication of a recommendation for termination of fluid administration. The indication of fluid responsiveness can indicate a response of stroke volume of the patient to fluid administration. The method can include determining a first confidence parameter corresponding to the first prediction of fluid responsiveness; and determining a second confidence parameter corresponding to the second prediction of fluid responsiveness. The fluid responsiveness of the patient can be further based at least in part on the first confidence parameter and the second confidence parameter.


In some cases, a system for determining fluid responsiveness of a patient can include a sensor interface and a processor in communication with the sensor interface. The sensor interface can be configured to connect to a non-invasive physiological sensor and to receive a sensor signal from the non-invasive physiological sensor. The non-invasive physiological sensor can be configured to emit light towards a tissue site of a patient, detect the light after it has interacted with the tissue site, and generate the sensor signal based at least in part on the detected light. The processor can be configured to determine a plethysmograph variability parameter associated with a plethysmograph waveform corresponding to the sensor signal. The plethysmograph waveform can include a plurality of pulses corresponding to pulsatile blood flow within the tissue site. The plethysmograph variability parameter can quantify variations in the plethysmograph waveform. The processor can be further configured to determine a first prediction of fluid responsiveness based at least in part on the plethysmograph variability parameter. The processor can be further configured to determine a second prediction of fluid responsiveness based at least in part on a fluid responsiveness parameter that is associated with an elevation of one or more limbs of the patient. The processor can be further configured to output an indication of fluid responsiveness of the patient based at least in part on the first prediction of fluid responsiveness and the second prediction of fluid responsiveness.


The patient monitoring device of any of the preceding paragraphs and/or any of the patient monitoring devices disclosed herein may include any combination of the following features described in this paragraph, among other features described herein. The plethysmograph variability parameter can correspond to a value associated with a pleth variability index (PVI). The fluid responsiveness parameter can include a measure of at least one of cardiac output, heart rate, or stroke volume. The elevation of the one or more limbs of the patient can be associated with a passive leg raising (PLR) test. The PLR test can be performed prior to administration of fluids to the patient. The PLR test can be performed during administration of fluids to the patient. The processor can be further configured to cause an action based on the fluid responsiveness of the patient, wherein the action can include at least one of initiating administration of fluids to the patient, terminating the administration of the fluids to the patient, causing a display to display an indication of a recommendation for fluid administration, or causing the display to display an indication of a recommendation for termination of fluid administration. The processor can be further configured to determine a first confidence parameter corresponding to the first prediction of fluid responsiveness; and determine a second confidence parameter corresponding to the second prediction of fluid responsiveness. The fluid responsiveness of the patient can be further based at least in part on the first confidence parameter and the second confidence parameter.


Any of the features of any of the methods described herein can be used with any of the features of any of the other methods described herein. Any of the features of any of the systems, devices, or methods illustrated in the figures or described herein can be used with any of the features of any of the other systems, devices, or methods illustrated in the figures or described herein.





BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings and the associated descriptions are provided to illustrate embodiments of the present disclosure and do not limit the scope of the claims.



FIG. 1 is an example block diagram of a patient monitoring device.



FIG. 2A is a perspective view of an example patient monitoring device including a hub and the patient monitoring device of FIG. 1.



FIG. 2B illustrates an example hardware block diagram of the hub of FIG. 2B.



FIG. 3 illustrates a perspective view of the back of the patient monitoring device of FIG. 2A.



FIG. 4 illustrates a pleth signal plotted on an intensity axis versus a time axis.



FIG. 5 is a flow diagram illustrative of an embodiment of a routine for assessing or predicting fluid responsiveness.



FIGS. 6A-6C illustrate embodiments of example GUIs that displays example graphics for instructing or implementing the PLR test on a patient.



FIG. 7 illustrates an embodiment of an example GUI that displays a fluid administration recommendation based on the hydration status and/or fluid responsiveness of the patient.





While the foregoing “Brief Description of the Drawings” references generally various embodiments of the disclosure, an artisan will recognize from the disclosure herein that such embodiments are not mutually exclusive. Rather, the artisan would recognize a myriad of combinations of some or all of such embodiments.


DETAILED DESCRIPTION


FIG. 1 is an example block diagram of a patient monitoring device 100. The patient monitoring device can include a docked portable patient monitor 100, which may be referred to herein as the patient monitoring device 100. The patient monitoring device 100 may advantageously include an oximeter, co-oximeter, respiratory monitor, depth of sedation monitor, noninvasive blood pressure monitor, vital signs monitor or the like, such as those commercially available from Masimo Corporation of Irvine, CA, and/or disclosed in U.S. Patent Publication Nos. 2002/0140675, 2010/0274099, 2011/0213273, 2012/0226117, 2010/0030040; U.S. Patent Application Ser. Nos. 61/242,792, 61/387,457, 61/645,570, 13/554,908 and U.S. Pat. Nos. 6,157,850, 6,334,065, and the like.


The patient monitoring device 100 can include a first processor 104, a display 106, and an OEM board 108. The patient monitoring device 100 further includes one or more cables 110 and an antenna 112 for wired and wireless communication, respectively.


The OEM board 108 can include an instrument board 114, a core or technical board 116, and memory 118. In some cases, the memory 118 can include a user interface module 120, a signal processing module 122, instrument configuration parameters 124, and local configuration parameters 126.


The patient monitoring device 100 may communicate with a variety of noninvasive and/or minimally invasive sensors 102 such as optical sensors with light emission and detection circuitry, acoustic sensors, devices that measure blood parameters from a finger prick, cuffs, ventilators, ECG sensors, pulse oximeters, and the like.


One or more of the sensors 102 can be attached to a medical patient. The sensors 102 can obtain physiological information from a medical patient and transmit this information to the technical board 116 through cables 130 or through a wireless connection (not shown). The physiological information can include one or more physiological parameters or values and waveforms corresponding to the physiological parameters.


The technical board 116 can receive physiological information from the sensors 102. The technical board 116 can include a circuit having a second processor, which may be the same as the first processor 104, and input ports for receiving the physiological information. The technical board 116 can access the signal processing module 122 to process the physiological information in the second processor. In addition, the technical board 116 can include one or more output ports, such as serial ports. For example, an RS232, RS423, or autobaud RS232 (serial interface standard) port or a universal serial bus (USB) port may be included in the technical board 116.


The technical board 116 and the signal processing module 122 can include a sensor processing system for the patient monitoring device 100. In some cases, the sensor processing system generates waveforms from signals received from the sensors 102. The sensor processing system may also analyze single or multiparameter trends to provide early warning alerts to clinicians prior to an alarm event. In addition, the sensor processing system can generate alarms in response to physiological parameters exceeding certain safe thresholds.


Example alerts include no communication with the patient monitoring device 100, alarm silenced on the patient monitoring device 100, instrument low battery (patient monitoring device 100), transmitter low battery, and/or indications of fluid responsiveness. Example physiological parameters include SpO2 levels, high and low SpO2, high and low PR, HbCO level, HbMET level, pulse rate, perfusion index, signal quality, HbCO, HbMET, PI, and desat index. Additional example alarms include SpO2 alarms, high and low SpO2 alarms, high and low PR, HbCO alarms, HbMET alarms, pulse rate alarms, no sensor alarms, sensor off patient alarms, sensor error, low perfusion index alarm, low signal quality alarm, HbCO alarm, HbMET alarm, PI trend alarm, and desat index alarm.


The instrument board 114 can receive the waveforms, alerts, alarms, and the like from the technical board 116. The instrument board 114 can include a circuit having a third processor, which may be the same as the first processor 104, and input ports for receiving the waveforms, alerts, and alarms from the technical board 116 and output ports for interfacing with the display 106, a speaker or other device capable of producing an audible indication. The instrument board 114 can access the user interface module 120 to process the waveforms, alerts, and alarms to provide indications of the waveforms, alerts, alarms or other data associated with the physiological parameters monitored by the sensors 102. The indications can be displayed on the display 106. In addition or alternatively, the alerts and alarms are audible. The indications, alerts, and alarms can be communicated to end-user devices, for example, through a hospital backbone, a hospital WLAN 16, and/or the Internet.


Additionally, the instrument board 114 and/or the technical board 116 may advantageously include one or more processors and controllers, busses, all manner of communication connectivity and electronics, memory, memory readers including EPROM readers, and other electronics recognizable to an artisan from the disclosure herein. Each board can include substrates for positioning and support, interconnect for communications, electronic components including controllers, logic devices, hardware/software combinations and the like to accomplish the tasks designated above and others.


An artisan will recognize from the disclosure herein that the instrument board 114 and/or the technical board 116 may include a large number of electronic components organized in a large number of ways.


Because of the versatility needed to process many different physiological parameters, the technical board 116 can further include a revision number or other indication of the circuit design and capabilities of a specific technical board 116.


Likewise, because of the versatility needed to display the processed physiological parameters for use by many different end users, the instrument board 114 can further include a revision number or other indication of the circuit design and capabilities of the specific instrument board.


Software is also subject to upgrading to increase its capabilities. The signal processing module 122 can further include a version number or other indication of the code found in the specific signal processing module 122. Likewise, the user interface module 120 can further include a version number or other indication of the code found on the specific user interface module 120.


Some or all of the serial numbers, the model numbers, and the revision numbers of the technical board 116 and the instrument board 114 that include the specific patient monitoring device 100 can be stored in the instrument configuration parameters 124. Further, the version numbers of the signal processing module 122 and the user interface module 120 are stored in the instrument configuration parameters 124. The instrument configuration parameters 124 can further include indications of the physiological parameters that are enabled, and indications of the physiological parameters that are capable of being enabled for the patient monitoring device 100.


The location of the patient monitoring device 100 can affect the sensitivity at which a physiological parameter is monitored. For example, a physiological parameter may be monitored with greater sensitivity when the patent monitoring device 100 is located in the neonatal intensive care unit (NICU), OR or surgical ICU than when it is located in an adult patient's room. In some cases, the location of the patient monitoring device 100 may affect the availability of the device for another patient. For example, a patient monitoring device 100 located in the hospital discharge area may be available for another patient, whereas one located in a patient's room may not be available anytime soon.


The local configuration parameters 126 can include a location of the patient monitoring device 100 within the facility, an indication of whether the device is configured for adult or pediatric monitoring, and the like.


The sensor 102 can include memory 128. The memory 128 can include information associated with the sensor 102, such as, but not limited to a sensor type, a sensor model number, a sensor revision number, a sensor serial number, and the like.


The patient monitoring device 100 can include a Radical-7® Rainbow SET Pulse Oximeter by Masimo Corporation, Irvine, CA The OEM board 108 can be produced by Masimo Corporation, Irvine, CA and used by others to produce patient monitoring devices.



FIG. 2A illustrates a perspective view of an example patient monitoring device, such as a medical monitoring hub with the docked portable patient monitoring device 100, the combination of which may also be referred to herein as a patient monitoring device or patient monitoring system 200. The hub includes a display 224, and a docking station 226, which can be configured to mechanically and electrically mate with the portable patient monitoring device 100, each housed in a movable, mountable and portable housing 228. The housing 228 includes a generally upright inclined shape configured to rest on a horizontal flat surface, although the housing 228 can be affixed in a wide variety of positions and mountings and include a wide variety of shapes and sizes.


The display 224 may present a wide variety of measurement and/or treatment data in numerical, graphical, waveform, or other display indicia 232. The display 224 can occupy much of a front face of the housing 228; although an artisan will appreciate the display 224 may include a tablet or tabletop horizontal configuration, a laptop-like configuration or the like. Other examples may include communicating display information and data to a table computer, smartphone, television, or any display system recognizable to an artisan. The upright inclined configuration of FIG. 2A presents display information to a caregiver in an easily viewable manner. The patient monitoring device 200 may display information for a variety of physiological parameters, such as but not limited to oxygen saturation (SpO2), hemoglobin (Hb), oxyhemoglobin (HbO2), total hemoglobin, carboxyhemoglobin, methemoglobin, perfusion index (Pi), pulse rate (PR) of blood pressure, temperature, electrocardiogram (ECG), motion data, accelerometer data, respiration, continuous blood pressure, pleth variability index (PVI), oxygen content, oxygen reserve index, acoustic respiration rate (RRa), respiration rate from the pleth, cardiac output, stroke volume, and/or fluid responsiveness.



FIG. 2B illustrates a simplified example hardware block diagram of the patient monitoring device 200. As shown in FIG. 2B, the housing 228 of the patient monitoring device 200 positions and/or encompasses an instrument board 202, a core or technical board 212, the display 224, memory 204, and the various communication connections, including serial ports 230, channel ports 222, Ethernet ports 205, nurse call port 206, other communication ports 208 including standard USB, or the like, and a docking station interface 210. The instrument board 202 can include one or more substrates including communication interconnects, wiring, ports and the like to enable the communications and functions described herein, including inter-board communications. The technical board 212 includes the main parameter, signal, and other processor(s) and memory. A portable monitor board (“RIB”) 214 includes patient electrical isolation for the monitor 100 and one or more processors. A channel board (“MID”) 216 controls the communication with the channel ports 222 including optional patient electrical isolation and power supply 218, and a radio board 220 includes components configured for wireless communications.


Additionally, the instrument board 202 and/or the technical board 212 may advantageously include one or more processors and controllers, busses, all manner of communication connectivity and electronics, memory, memory readers including EPROM readers, and other electronics recognizable to an artisan from the disclosure herein. Each board can include substrates for positioning and support, interconnect for communications, electronic components including controllers, logic devices, hardware/software combinations and the like to accomplish the tasks designated above and others.


An artisan will recognize from the disclosure herein that the instrument board 202 and or the technical board 212 may include a large number of electronic components organized in a large number of ways.


Because of the versatility needed to process many different physiological parameters, the technical board 212 can further include a revision number or other indication of the circuit design and capabilities of a specific technical board 212.


Likewise, because of the versatility needed to display the processed physiological parameters for use by many different end users, the instrument board 202 can further include a revision number or other indication of the circuit design and capabilities of the specific instrument board 202.


The memory 204 can include a user interface module 240, a signal processing module 242, instrument configuration parameters 244, and local configuration parameters 246.


The instrument board 202 can access the user interface module 240 to process the waveforms, alerts, and alarms to provide indications of the waveforms, alerts, alarms or other data associated with the physiological parameters for the patient monitoring device 200. The technical board 212 can access the signal processing module 242 to process the physiological information for the patient monitoring device 200.


Software for the patient monitoring device 200 is also subject to upgrading to increase its capabilities. The signal processing module 242 can further include a version number or other indication of the code found in the specific signal processing module 242. Likewise, the user interface module 240 can further include a version number or other indication of the code found on the specific user interface module 240.


Some or all of the serial numbers, the model numbers, and the revision numbers of the technical board 212 and the instrument board 202 that include the specific patient medical monitoring hub 150 can be stored in the instrument configuration parameters 244. Further, the version numbers of the signal processing module 242 and the user interface module 240 can be stored in the instrument configuration parameters 244. The instrument configuration parameters 244 further include indications of the physiological parameters that are enabled, and indications of the physiological parameters that are capable of being enabled for the patient monitoring device 200.


The local configuration parameters 246 can include a location of the patient monitoring device 200 within the facility, an indication of whether the device is configured for adult or pediatric monitoring, and the like.


The patient monitoring device 200 can include a Root® Patient Monitoring and Connectivity Platform by Masimo Corporation, Irvine, CA that includes the Radical-7® also by Masimo Corporation, Irvine, CA.



FIG. 3 illustrates an example perspective view of the back of the patient monitoring device 200 of FIG. 2A, showing an example serial data inputs. The inputs can include RJ 45 ports. As is understood in the art, these ports include data ports similar to those found on computers, network routers, switches and hubs. A plurality of these ports can be used to associate data from various devices with the specific patient identified in the patient monitoring device 200. FIG. 3 also shows a speaker, the nurse call connector, the Ethernet connector, the USBs, a power connector and a medical grounding lug.


Patient Hydration


Dehydration is a condition that can occur when the loss of body fluids, mostly water, exceeds the amount that is taken in. For example, the body is constantly losing fluids through breathing, sweat loss, and urinary excretion. In addition, the body can lose fluids as a result of preoperative fasting, surgical blood loss, fluid shifts or other pathologic processes. With dehydration, more water is moving out of individual cells and then out of the body than the amount of water that is taken in. Medically, dehydration usually means a person has lost enough fluid so that the body begins to lose its ability to function normally.


The severity of dehydration can vary based on the amount of fluids in the patient's body. For example, in some cases, dehydration can be classified based on levels or a degree of dehydration. For instance, in some cases, if a patient is dehydrated, a level of the patient's dehydration can be classified as one of mild dehydration, moderate dehydration, or severe dehydration, or somewhere in between. In some cases, mild dehydration corresponds to a 3% to 5% drop in fluids as compared to normal or average fluid levels of the patient, moderate dehydration corresponds to a 6% to 10% drop in fluids as compared to normal or average fluid levels of the patient, and severe dehydration corresponds to more than a 10% drop in fluids as compared to normal or average fluid levels of the patient. However, it will be understood that the range or categorizations of degrees of dehydration can vary across embodiments. For example, in some cases, patient hydration can be binary: dehydrated or not dehydrated. Furthermore, in some cases, patient hydration can correspond to a sliding scale, such as a scale from 0 to 100. Further still, the ranges or categorizations of degrees of dehydration can vary based on a patient's age, gender, weight, etc.


Dehydration can itself be dangerous. Furthermore, dehydration can cause common conditions including, but not limited to, constipation, falls, urinary tract infections, pressure ulcers, malnutrition, incontinence, confusion, acute kidney injury, cardiac disease or venous thromboembolism. For some patients, preventing or treating dehydration is difficult without assistance. For instance, a patient may not be able to drink or consume fluids. In some such cases, fluids can be administered to the patient, for example, intravenously. However, in many instances, dehydrated can be difficult to detect or predict. Accordingly, it can be desirable to gage an accurate assessment of patient hydration or dehydration.


In some cases, the system can obtain an accurate assessment of patient hydration or dehydration (non-limiting example, whether a hydration threshold is satisfied or not satisfied) using physiological data of the patient. For example, the system can include (or receive signals from) a pulse oximeter, which can be positioned on the patient. In some cases, the pulse oximeter can detect a pleth signal, and can communicate the pleth signal, or an indication thereof, to the system.



FIG. 4 illustrates a pleth signal 400 plotted on an intensity axis 401 versus a time axis 402. The pleth signal 400 has multiple pulses 410, which correspond to pulsatile blood flowing within a tissue site. As illustrated, each pulse 410 is characterized by a plurality of features such as a peak amplitude 412, valley amplitude 414, and period 416. Further, pleth signal 400 defines a pleth envelope 450 interpolated from pulse peaks 412 and pulse valleys 414.


Perfusion values, or a perfusion index (PI), can be defined for each pulse 410. PI generally reflects the amplitude of the waveform and is calculated as the pulsatile infrared signal (AC 420 or variable component), indexed against the non-pulsatile infrared signal (DC 430 or constant component). PI can be expressed as a percentage (for example, 0.02-20%). In some cases, PI is the ratio of the pulsing blood to non-pulsing blood flow, and can be determined using the following equation:









PI
=


A





C


D





C






(

Equation





1

)








where AC can represent a peak amplitude 412 minus a valley amplitude 414 for a particular pulse, and DC can represent a peak amplitude 412 for a particular pulse. Among other things, PI can be used to indicate a strength of blood flow a measurement site. In some cases, DC can represent a value other than peak amplitude 412, such as a valley amplitude 414 or an average of peak amplitude 412 and valley amplitude 414, to name a few.


In some cases, a patient monitoring device, such as the patient monitoring device 100 of FIG. 1, can identify a pleth variability parameter that is responsive to variations of the pleth. In some cases, a pleth variability parameter is a clinically useful hemodynamic measurement because it can respond to changes in patient physiology, thereby acting as a useful indicator of various physiological conditions or the efficacy of treatment for those conditions. Advantageously, pleth variability measures may provide a numerical indication of a person's physical condition or health. For example, changes in a pleth variability parameter may be representative of changes in physiologic factors such as patient hydration.


One variability measure is a Pleth Variability Index (PVI or PVi®) (developed by Masimo® Corporation, Irvine, CA, USA)) as described in greater detail in U.S. Pub. No. 2008/0188760, filed Dec. 7, 2007, and entitled “PLETHYSMOGRAPH VARIABILITY PROCESSOR,” which is hereby incorporated by reference herein in its entirety.


PVI can be based on perfusion index (PI) variations during a respiratory cycle. For example, PVI can be a measure of dynamic changes in PI that occur during one or more complete respiratory cycles. As illustrated from Equation 2 below, the calculation for PVI can be accomplished by measuring changes in PI over a time interval where one or more complete respiratory cycles have occurred, and can be determined using the following equation:









PVI
=




PI

m





ax


-

PI

m





i





n




PI

m





ax



*
100





(

Equation





2

)







In some cases, PVI can be automatically or continuously calculated and can represent respiratory variations in the plethysmographic waveform. Furthermore, in some cases, PVI may be indicative of or correlated with patient hydration or dehydration. As a non-limiting example, in some cases, a relatively lower PVI can indicate that the patient's hydration level does not satisfy a hydration threshold (e.g., the patient is dehydrated). As a corollary, a relatively high PVI can indicate that the patient's hydration level satisfies a hydration threshold (e.g., the patient is not dehydrated). However, it will be understood that, in some cases, a relatively low PVI can indicate that the patient's hydration level satisfies a hydration threshold and/or a relatively high PVI can indicate that the patient's hydration level does not satisfy a hydration threshold. In some cases, PVI can be displayed as a percentage (numerical value) and/or a trend graph. Similarly, the patient monitoring device can display (or cause a display to display) an indication of the patient's hydration status (for example, dehydrated, hydrated, no dehydrated, mildly dehydration, moderately dehydration, or severely dehydration mild dehydration, etc.) based at least in part on PVI. As another example, in some cases, the patient monitoring device can provide an indication to (or control a device to) initiate administration of fluids, continue administration of fluids, or terminate administration of fluids based at least in part on PVI. For example, in some cases, based on a determination that the patient is dehydrated, the patient monitoring device can provide an indication to (or control a device to) initiate administration of fluids or continue administration of fluids. As a corollary, in some cases, based on a determination that the patient is not dehydrated, the patient monitoring device can provide an indication to (or control a device to) terminate administration of fluids.


Cardiac Output


Cardiac output can refer to an amount or volume of blood that the heart pumps through the circulatory system, and is generally expressed in liters per minute. Sufficient cardiac output (that is, a cardiac output that satisfies a threshold cardiac output) helps keep blood pressure at the levels needed to supply oxygen-rich blood to the brain and other vital organs. In some cases, cardiac output can be calculated using the following equation:

CO=HR×SV  (Equation 3)

where CO is the Cardiac output, HR is heart rate (e.g., the number of heart beats per minute (bpm)), and SV is stroke volume (e.g., the amount of blood pumped from the left (or right) ventricle of the heart in one contraction). Accordingly, the cardiac output can be a function of heart rate and stroke volume, and thus, in some cases, the factors affecting stroke volume or heart rate may also affect cardiac output.


As a non-limiting example, for someone weighing about 70 kg (154 lbs.), a healthy heart with a normal cardiac output can pump about 5 to 6 liters of blood every minute when a person is resting. During exercise, the body may need three or four times its normal cardiac output, because the muscles need more oxygen. Thus, during exercise, the heart typically beats faster (known as increased heart rate) so that more blood flows out to the body. The heart can also increase its stroke volume by pumping more forcefully or increasing the amount of blood that fills the left ventricle before it pumps. Generally, an increase in cardiac output can be favorable or desired, as it can indicate an increase in the supply of oxygen-rich blood. In contrast, a decrease in cardiac output can be unfavorable or not desired, as it can indicate a decrease in the supply of oxygen-rich blood.


Fluid Responsiveness


Volume expansion can be applied to increase an amount of fluid present in a patient's body, and is frequently used before, during, or after surgery to correct dehydration or fluid deficits created by, for example, preoperative fasting, surgical blood loss, sweat loss, urinary excretion, fluid shifts or other pathologic processes. Techniques for volume expansion include, among other methods, oral rehydration therapy (for example, drinking), intravenous therapy (for example, delivering liquid substances directly into a vein), rectal therapy (for example, with a Murphy drip), or by hypodermoclysis (for example, the direct injection of fluid into the subcutaneous tissue).


In general, the objective of volume expansion is to improve oxygen delivery or overall hemodynamic function. However, some patients may not respond to volume expansion with improved oxygen delivery or improved overall hemodynamic function. For example, these patients may not respond to the volume expansion with an increase in stroke volume or cardiac output. In these patients, volume expansion can be either ineffective or deleterious, and can result in worsening oxygen delivery, inducing systemic and pulmonary edema or, in some cases, cardiac failure. In some cases, patients that do not respond to volume expansion with improved oxygen delivery or improved overall hemodynamic function are referred to as being fluid unresponsive. In some cases, patients that do respond to volume expansion with improved oxygen delivery or improved overall hemodynamic function are referred to as being fluid responsive. Thus, in some cases, a patient can be categorized as fluid unresponsive or fluid responsive based on how he or she will respond to volume expansion (sometimes referred to as a patient's fluid responsiveness).


As described herein, some patient's may be fluid unresponsive. Thus, it can be important to determine or predict a patient's fluid responsiveness (e.g. how a patient will respond to volume expansion) prior to administering fluids. In other words, prior to fluid administration, it can be important to determine or predict a patient's fluid responsiveness (or how fluid administration will affect a patient's cardiac output). A patient identified as someone that will respond to volume expansion with an increase in cardiac output such that the cardiac output satisfies a threshold cardiac output (or that the increase in cardiac output satisfies a threshold increase in cardiac output) can be classified as fluid responsive. In contrast, a patient identified as someone that will not respond to volume expansion with a cardiac output that satisfies a threshold cardiac output can be classified as fluid unresponsive. In some cases, an indication of a patient's fluid responsiveness can include an indication that the patient is fluid responsive, fluid unresponsive, or somewhere in between.


Although some static and dynamic cardiopulmonary indices have been used to predict fluid responsiveness, many of these measures generally have low predictive value, or can risk fluid overload (the condition of having too much fluid in the body, or the state of one of the chambers of the heart in which too large a volume of blood exists within it for it to function efficiently). For example, a fluid challenge can include administering fluids to patients in order to assess their response to fluid therapy and guide further treatment decisions. By administering a small amount of fluid in a short period of time, the clinician can assess the patient's fluid responsiveness. However, because volume expansion includes administering fluid to the patient, a fluid challenge can risk fluid overload.


Passive Leg Raising (PLR) Test


In some cases, the system can utilize information obtained as a result of the patient performing or being administered a passive leg raising (PLR) test to determine the patient's fluid responsiveness. The PLR test can vary across embodiments, but is generally a non-invasive, bedside test that involves elevating a patient's legs, and can be used to evaluate whether a patient will benefit from volume expansion. In some cases, the PLR test can be used to determine whether cardiac output respond such that it satisfies or does not satisfy a cardiac output threshold as a result of volume expansion.


In general, the PLR test involves raising the legs of a patient (without her active participation), which causes gravity to pull blood from the legs, thus increasing circulatory volume available to the heart, sometimes known as cardiac preload. The PLR test can be performed with the patient's active participation. For instance, the patient can actively raise his or legs. The PLR test can be performed with the patient's active participation. By transferring a volume of blood (for example, around 300 mL) from the lower body toward the heart, PLR mimics a fluid challenge. However, no fluid is infused and the hemodynamic effects are rapidly reversible, thereby avoiding the risks of fluid overload.


A method for performing a PLR test can include a sequence of steps. For example, the PLR test generally includes some combination of the following steps: (1) placing the patient in a semi-recumbent position (the patient's head and torso are positioned upright at an angle of about 45° relative to the patient's legs, which are resting flat on the table); (2) assessing the cardiac output. Here, the patient's heart rate, stroke volume, or the like can be identified by the system, or cardiac output can be determined; (3) moving the patient to a recumbent position (the patient's legs are raised and torso is lowered, where, ultimately, the patient is lying on her back with her feet raised at an angle of about 45°. Here, it may be beneficial not to have the patients elevate her legs manually because it may provoke pain, discomfort, or awakening that can cause adrenergic stimulation, giving false readings of cardiac output by increasing heart rate); (4) re-assessing the cardiac output. Here, the patient's heart rate, stroke volume, or the like can be identified by the system, or cardiac output can be determined; (5) returning the patient to a semi-recumbent position; and (6) re-assessing the cardiac output. Here, the patient's heart rate, stroke volume, or the like can be identified by the system, or cardiac output can be determined.


In general, the PLR test can be can used to assess fluid responsiveness without any fluid challenge, where the latter can lead to fluid overload. The real-time effects of the PLR test on hemodynamic parameters such as blood pressure, heart rate, or cardiac output can be used to guide the assessments on the patient's fluid responsiveness. For example, in some cases, if the patient's cardiac output responds such that it satisfies a threshold cardiac output, then it can be determined that the patient is fluid responsive. In contrast, in some cases, if the patient's cardiac output responds such that it does not satisfy a threshold cardiac output, then it can be determined that the patient is fluid unresponsive.


Flow Diagrams



FIG. 5 is a flow diagram illustrative of an embodiment of a routine 500, implemented by a processor, for assessing or predicting fluid responsiveness. One skilled in the relevant art will appreciate that the elements outlined for routine 500 can be implemented by one or more computing devices that are associated with the system 200, such as the processor 104 or the monitoring device 100. Accordingly, routine 500 has been logically associated as being generally performed by the processor 104 of FIG. 1. However, the following illustrative embodiment should not be construed as limiting. Furthermore, it will be understood that the various blocks described herein with reference to FIG. 5 can be implemented in a variety of orders. For example, the processor 104 can implement some blocks concurrently or change the order, as desired. Furthermore, it will be understood that fewer, more, or different blocks can be used as part of the routine 500.


At block 502, the processor 104 receives a sensor signal corresponding to a non-invasive physiological sensor. As described herein, the non-invasive physiological sensor, such as sensor 102 of FIG. 1, can include at least one emitter configured to emit light at one or more wavelengths. Further, the non-invasive sensor can include a detector configured to detect the light from the least one emitter after the light has interacted with the tissue site of a patient, and generate the sensor signal based at least in part on the detected light. For example, the non-invasive physiological sensor can be attached to the patient, such as to the patient's finger.


At block 504, the processor 104 determines a plethysmograph variability parameter based at least in part on the sensor signal. In some cases, the plethysmograph variability parameter can includes a value that relates or quantifies changes in patient physiology. For example, in some cases, the plethysmograph variability parameter can reflect variations that occur during the respiratory cycle or changes in physiologic factors such as changes in fluid responsiveness, volemia, ventricular preload, etc.


The plethysmograph variability parameter can be determined using one or more of various techniques, such as any one or more of the techniques disclosed in U.S. Patent Publication No. 2013/0296713, filed Apr. 8, 2013, which is hereby incorporated by reference in its entirety. For example, the processor 104 can determine perfusion values, or a perfusion index (PI), from pulses of a plethysmograph waveform that corresponds to the sensor signal. Furthermore, the processor 104 can determine the plethysmograph variability parameter based on the perfusion values or the PI. For instance, the determination of the plethysmograph variability parameter can include calculating a difference between perfusion values and normalizing the difference. In some cases, the plethysmograph variability parameter corresponds to one or more plethysmograph variability index (PVI) values. For example, a PVI value can be a measure of the dynamic changes in the Perfusion Index (PI) that occur during one or more complete respiratory cycles.


At block 506, the processor 104 determines a prediction of fluid responsiveness or unresponsiveness based at least in part on the plethysmograph variability parameter. For example, in some cases, the plethysmograph variability parameter includes a numerical value. In some such cases, a relatively higher plethysmograph variability parameter may indicate fluid responsiveness. For example, a higher plethysmograph variability parameter may indicate more variance in the perfusion values and a greater likelihood that the patient will respond to fluid administration with an increase in cardiac output. As a corollary, in some such cases, a relatively lower plethysmograph variability parameter may indicate fluid unresponsiveness. For example, a lower plethysmograph variability parameter may indicate less variance in the perfusion values and therefore a lower likelihood that the patient will respond to fluid administration with an increase in cardiac output.


In some cases, the processor 104 can further determine a confidence value associated with the prediction of fluid responsiveness or unresponsiveness. For example, in some cases, the confidence in a prediction of fluid responsiveness increases (i.e., a higher confidence) as the plethysmograph variability parameter increases and decreases (i.e., a lower confidence) as the plethysmograph variability parameter decreases. As a corollary, in some cases, the confidence in a prediction of fluid unresponsiveness increases as the plethysmograph variability parameter decreases and decreases as the plethysmograph variability parameter increases.


At block 508, the processor 104 determines a prediction of fluid responsiveness or unresponsiveness based at least in part on a fluid responsiveness parameter that is associated with an elevation of one or more limbs of the patient. For example, in some cases, some variance of a passive leg raise (PLR) test can be performed on the patient. As described herein, a PLR test is a non-invasive, bedside test, which can results in the elevation of one or more limbs (e.g., one or more legs) of the patient.


In some cases, the PLR test can be automated or semi-automated. For example, the processor 104 can cause the PLR test to begin, for instance by controlling movement of a patient's bed. In some cases, the PLR test can be performed manually, such as by a physician. In some cases, the processor 104 can provide an instruction to perform the PLR test. The instruction can include an auditory, visual or other indication. In some cases, the processor 104 can provide instructions throughout the PLR test. For example, the processor 104 can generate a graphical user interface (GUI) that displays a graphical indication of one or more steps of the PLR test. In some cases, the processor 104 can cause a display (for example, display 106 or 224) to display a visual walkthrough of the steps of the PLR test. FIGS. 6A-6C illustrate an embodiment of an example GUI that displays example graphics for instructing or implementing the PLR test on a patient. As illustrated, for one or more steps of the PLR test, the GUI can show a graphical depiction of the orientation of the patient and/or the patient's bed. In addition or alternatively, the GUI can include instructions for the caregiver, such as an indication of when to obtain results from the PLR test, a timer or alarm for a particular step, or the like.


The fluid responsiveness parameter can vary across embodiments. For example, in some cases, the fluid responsiveness parameter includes a measure of cardiac output. As another example, in some cases, the fluid responsiveness parameter includes a measure of heart rate. As another example, in some cases, the fluid responsiveness parameter includes a measure of stroke volume. The fluid responsiveness parameter can be determined at one or more of various stages of the PLR test. For example, the fluid responsiveness parameter can be determined prior to performance of the PLR test, during the PLR test, and/or after the PLR test has completed. Furthermore, the fluid responsiveness parameter can be measured in real-time by one or more sensors and/or can be calculated by the processor 104 using sensor data. Alternatively, in some cases, a physician and/or medical device can monitor the fluid responsiveness parameter of the patient, and the physician can enter fluid responsiveness parameter as an input to the processor 104.


The processor 104 can determine a prediction of fluid responsiveness or unresponsiveness in various ways. For example, changes in the fluid responsiveness parameter can be used to guide the determination of the prediction. For example, in some cases, a first fluid responsiveness parameter is measured prior to during the PLR test and a second fluid responsiveness parameter is measured during or after PLR test. In some such cases, the processor 104 can determine a prediction of fluid responsiveness or unresponsiveness based one a comparison for the first fluid responsiveness parameter and the second fluid responsiveness parameter. For example, if the second fluid responsiveness parameter increases (for example, by a threshold amount) relative to the first fluid responsiveness parameter, then the processor 104 can determine a prediction of fluid responsiveness. Put another way, in some cases, if the PLR test causes the fluid responsiveness parameter to increase (for example, by a threshold amount), the processor 104 can determine a prediction of fluid responsiveness. As a corollary, in some cases, if the PLR test causes the fluid responsiveness parameter to stay the same, decrease, or not increase by threshold amount, the processor 104 can determine a prediction of fluid unresponsiveness.


In some cases, the processor 104 can further determine a confidence value associated with the prediction of fluid responsiveness or unresponsiveness. For example, in some cases, the confidence in a prediction of fluid responsiveness or unresponsiveness is based on the amount that the fluid responsiveness parameter changes over time. For example, for a prediction of fluid responsiveness, a relatively larger increase in the fluid responsiveness parameter can result in a higher confidence value, while a relatively smaller increase can result in a lower confidence value. As another example, for a prediction of fluid unresponsiveness, no increase or a decreases in the fluid responsiveness parameter can result in a higher confidence value, while an increase in the fluid responsiveness parameter can result in a lower confidence value.


At block 508, the processor 104 outputs an indication of an overall prediction of fluid responsiveness or fluid responsiveness. For example, the processor 104 can determine the overall prediction of fluid responsiveness or fluid responsiveness based at least in part on the determinations at block 506 and/or block 508. For example, the overall prediction of fluid responsiveness or fluid responsiveness can be based at least in part on one or more of the prediction of fluid responsiveness or unresponsiveness using the plethysmograph variability parameter, the prediction of fluid responsiveness or unresponsiveness using the fluid responsiveness parameter, and/or confidence values associated therewith.


As an example, if both blocks 506 and 508 return a prediction of fluid responsiveness, then the processor 104 can output an indication of fluid responsiveness. As an example, if both blocks 506 and 508 return a prediction of fluid unresponsiveness, then the processor 104 can output an indication of fluid unresponsiveness. In some cases, if one of blocks 506 and 508 returns a prediction of fluid unresponsiveness and one of blocks 506 and 508 returns a prediction of fluid responsiveness, then the processor 104 can output an error code. In some cases, if one of blocks 506 and 508 returns a prediction of fluid unresponsiveness and one of blocks 506 and 508 returns a prediction of fluid responsiveness, then the processor 104 can output the prediction of whichever method produced a higher confidence value, as described herein.


It will be understood that the various blocks described herein can be implemented in a variety of orders, and that the processor 104 can implement one or more of the blocks concurrently and/or change the order, as desired. For example, in some cases, any of blocks 502, 504, 506 and/or 508 can be implemented prior to or currently with any other blocks 502. Furthermore, it will be understood that fewer, more, or different blocks can be used as part of the routine 500. For example, the routine 500 can include blocks for controlling a device to administer fluids to the patient or terminate administration of fluids to the patient. For instance, in some cases, based on a prediction of fluid responsiveness, the processor can cause fluid to be administered to the patient, either by operating or controlling a medical device, such as an infusion pump, to administer fluids to the patient or by outputting an indication to administer fluids. As another example, in some cases, based on a prediction of fluid unresponsiveness, the processor can cause administration of fluid to be terminated, either by operating or controlling a medical device, such as an infusion pump, or by outputting an indication to termination administration of fluids.


Furthermore, the processor 104 can cause display on the GUI of one or more instructions, which, when viewed, can indicate how to perform the PLR test, or a duration over which to hold a specific step of the PLR test. Furthermore, in some cases, rather than or in addition to predicting fluid responsiveness or fluids unresponsiveness, the processor 104 can identify a hydration status of a patient. In some cases, if the patient is hydrated, the processor 104 doesn't initiate the routine 500. In some cases, the processor 104 initiates the routine 500 based on a determination that the patient is dehydrated. Furthermore, in some cases, the routine 500 can omit certain blocks, such as, but not limited to, blocks 502, 504, 506, and/or 508.


Terminology

The term “and/or” herein has its broadest least limiting meaning which is the disclosure includes A alone, B alone, both A and B together, or A or B alternatively, but does not require both A and B or require one of A or one of B. As used herein, the phrase “at least one of” A, B, “and” C should be construed to mean a logical A or B or C, using a non-exclusive logical or.


The following description is merely illustrative in nature and is in no way intended to limit the disclosure, its application, or uses. For purposes of clarity, the same reference numbers will be used in the drawings to identify similar elements. It should be understood that steps within a method may be executed in different order without altering the principles of the present disclosure.


Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.


While certain embodiments have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of protection. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms. Furthermore, various omissions, substitutions and changes in the form of the methods and systems described herein may be made. Those skilled in the art will appreciate that in some embodiments, the actual steps taken in the processes illustrated or disclosed may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. For example, the actual steps or order of steps taken in the disclosed processes may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. For instance, the various components illustrated in the figures may be implemented as software or firmware on a processor, controller, ASIC, FPGA, or dedicated hardware. Hardware components, such as processors, ASICs, FPGAs, and the like, can include logic circuitry. Furthermore, the features and attributes of the specific embodiments disclosed above may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure.


User interface screens illustrated and described herein can include additional or alternative components. These components can include menus, lists, buttons, text boxes, labels, radio buttons, scroll bars, sliders, checkboxes, combo boxes, status bars, dialog boxes, windows, and the like. User interface screens can include additional or alternative information. Components can be arranged, grouped, displayed in any suitable order.


Although the present disclosure includes certain embodiments, examples and applications, it will be understood by those skilled in the art that the present disclosure extends beyond the specifically disclosed embodiments to other alternative embodiments or uses and obvious modifications and equivalents thereof, including embodiments which do not provide all of the features and advantages set forth herein. Accordingly, the scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments herein, and may be defined by claims as presented herein or as presented in the future.


Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, or steps. Thus, such conditional language is not generally intended to imply that features, elements, or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, or steps are included or are to be performed in any particular embodiment. The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list. Further, the term “each,” as used herein, in addition to having its ordinary meaning, can mean any subset of a set of elements to which the term “each” is applied.


Conjunctive language such as the phrase “at least one of X, Y, and Z,” unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain embodiments require the presence of at least one of X, at least one of Y, and at least one of Z.


Language of degree used herein, such as the terms “approximately,” “about,” “generally,” and “substantially” as used herein represent a value, amount, or characteristic close to the stated value, amount, or characteristic that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, “generally,” and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount. As another example, in certain embodiments, the terms “generally parallel” and “substantially parallel” refer to a value, amount, or characteristic that departs from exactly parallel by less than or equal to 15 degrees, 10 degrees, 5 degrees, 3 degrees, 1 degree, or 0.1 degree.


The scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments in this section or elsewhere in this specification, and may be defined by claims as presented in this section or elsewhere in this specification or as presented in the future. The language of the claims is to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive.

Claims
  • 1. A patient monitoring device for determining fluid responsiveness of a patient, the patient monitoring device comprising: one or more of non-invasive physiological sensors configured to obtain physiological information from the patient, and further configured to emit light towards a tissue site of a patient, and detect the light after it has interacted with the tissue site, and generate a sensor signal based at least in part on the detected light;a sensor interface configured to receive the sensor signal from the one or more non-invasive physiological sensors; anda processor in communication with the sensor interface and configured to: automatically determine a plethysmograph variability parameter associated with a plethysmograph waveform corresponding to the sensor signal, wherein the plethysmograph waveform comprises a plurality of pulses corresponding to pulsatile blood flow within the tissue site, wherein the plethysmograph variability parameter corresponds to a value associated with a pleth variability index (PVI) and quantifies variations in the plethysmograph waveform,determine a first prediction of fluid responsiveness based at least in part on the plethysmograph variability parameter,determine a first confidence value associated with the first prediction of fluid responsiveness based on a value of the plethysmograph variability parameter,send a control signal to cause a bed of the patient to move in order to cause a change in elevation of one or more limbs of the patient,determine a second prediction of fluid responsiveness based at least in part on a fluid responsiveness parameter that is associated with an elevation of the one or more limbs of the patient that is associated with a passive leg raising (PLR) test,determine a second confidence value associated with the second prediction of fluid responsiveness based on a change in the fluid responsiveness parameter,output an indication of fluid responsiveness of the patient based at least in part on the first confidence value, the second confidence value, the first prediction of fluid responsiveness, and the second prediction of fluid responsiveness, andcause an action, based on the fluid responsiveness of the patient, related to administration of fluid to the patient.
  • 2. The patient monitoring device of claim 1, wherein the fluid responsiveness parameter comprises a measure of at least one of cardiac output, heart rate, or stroke volume.
  • 3. The patient monitoring device of claim 1, wherein the elevation of one or more limbs is performed prior to administration of fluids to the patient.
  • 4. The patient monitoring device of claim 1, wherein the elevation of the one or more limbs is performed during administration of fluids to the patient.
  • 5. The patient monitoring device of claim 1, wherein the treatment recommendation comprises at least one of a recommendation to administer the fluids to the patient, a recommendation to not administer the fluids to the patient, or a recommendation to terminate administration of the fluids to the patient.
RELATED APPLICATIONS

The application claims priority to U.S. Provisional Application No. 62/755,802, filed Nov. 5, 2018, entitled “System To Manage Patient Hydration,” which is hereby incorporated by reference in its entirety.

US Referenced Citations (1270)
Number Name Date Kind
4960128 Gordon et al. Oct 1990 A
4964408 Hink et al. Oct 1990 A
5041187 Hink et al. Aug 1991 A
5069213 Polczynski Dec 1991 A
5163438 Gordon et al. Nov 1992 A
5319355 Russek Jun 1994 A
5337744 Branigan Aug 1994 A
5341805 Stavridi et al. Aug 1994 A
D353195 Savage et al. Dec 1994 S
D353196 Savage et al. Dec 1994 S
5377676 Vari et al. Jan 1995 A
D359546 Savage et al. Jun 1995 S
5431170 Mathews Jul 1995 A
5436499 Namavar et al. Jul 1995 A
D361840 Savage et al. Aug 1995 S
D362063 Savage et al. Sep 1995 S
5452717 Branigan et al. Sep 1995 A
D363120 Savage et al. Oct 1995 S
5456252 Vari et al. Oct 1995 A
5479934 Imran Jan 1996 A
5482036 Diab et al. Jan 1996 A
5490505 Diab et al. Feb 1996 A
5494043 O'Sullivan et al. Feb 1996 A
5533511 Kaspari et al. Jul 1996 A
5534851 Russek Jul 1996 A
5561275 Savage et al. Oct 1996 A
5562002 Lalin Oct 1996 A
5590649 Caro et al. Jan 1997 A
5602924 Durand et al. Feb 1997 A
5632272 Diab et al. May 1997 A
5638816 Kiani-Azarbayjany et al. Jun 1997 A
5638818 Diab et al. Jun 1997 A
5645440 Tobler et al. Jul 1997 A
5671914 Kalkhoran et al. Sep 1997 A
5685299 Diab et al. Nov 1997 A
5726440 Kalkhoran et al. Mar 1998 A
D393830 Tobler et al. Apr 1998 S
5743262 Lepper, Jr. et al. Apr 1998 A
5747806 Khalil et al. May 1998 A
5750994 Schlager May 1998 A
5758644 Diab et al. Jun 1998 A
5760910 Lepper, Jr. et al. Jun 1998 A
5769785 Diab et al. Jun 1998 A
5782757 Diab et al. Jul 1998 A
5785659 Caro et al. Jul 1998 A
5791347 Flaherty et al. Aug 1998 A
5810734 Caro et al. Sep 1998 A
5823950 Diab et al. Oct 1998 A
5830131 Caro et al. Nov 1998 A
5833618 Caro et al. Nov 1998 A
5860919 Kiani-Azarbayjany et al. Jan 1999 A
5890929 Mills et al. Apr 1999 A
5904654 Wohltmann et al. May 1999 A
5919134 Diab Jul 1999 A
5934925 Tobler et al. Aug 1999 A
5940182 Lepper, Jr. et al. Aug 1999 A
5987343 Kinast Nov 1999 A
5995855 Kiani et al. Nov 1999 A
5997343 Mills et al. Dec 1999 A
6002952 Diab et al. Dec 1999 A
6010937 Karam et al. Jan 2000 A
6011986 Diab et al. Jan 2000 A
6027452 Flaherty et al. Feb 2000 A
6036642 Diab et al. Mar 2000 A
6040578 Malin et al. Mar 2000 A
6045509 Caro et al. Apr 2000 A
6066204 Haven May 2000 A
6067462 Diab et al. May 2000 A
6081735 Diab et al. Jun 2000 A
6088607 Diab et al. Jul 2000 A
6110522 Lepper, Jr. et al. Aug 2000 A
6115673 Malin et al. Sep 2000 A
6124597 Shehada Sep 2000 A
6128521 Marro et al. Oct 2000 A
6129675 Jay Oct 2000 A
6144868 Parker Nov 2000 A
6151516 Kiani-Azarbayjany et al. Nov 2000 A
6152754 Gerhardt et al. Nov 2000 A
6157850 Diab et al. Dec 2000 A
6165005 Mills et al. Dec 2000 A
6184521 Coffin, IV et al. Feb 2001 B1
6206830 Diab et al. Mar 2001 B1
6229856 Diab et al. May 2001 B1
6232609 Snyder et al. May 2001 B1
6236872 Diab et al. May 2001 B1
6241683 Macklem et al. Jun 2001 B1
6253097 Aronow et al. Jun 2001 B1
6255708 Sudharsanan et al. Jul 2001 B1
6256523 Diab et al. Jul 2001 B1
6263222 Diab et al. Jul 2001 B1
6278522 Lepper, Jr. et al. Aug 2001 B1
6280213 Tobler et al. Aug 2001 B1
6280381 Malin et al. Aug 2001 B1
6285896 Tobler et al. Sep 2001 B1
6301493 Marro et al. Oct 2001 B1
6308089 von der Ruhr et al. Oct 2001 B1
6317627 Ennen et al. Nov 2001 B1
6321100 Parker Nov 2001 B1
6325761 Jay Dec 2001 B1
6334065 Al-Ali et al. Dec 2001 B1
6343224 Parker Jan 2002 B1
6349228 Kiani et al. Feb 2002 B1
6360114 Diab et al. Mar 2002 B1
6368283 Xu et al. Apr 2002 B1
6371921 Caro et al. Apr 2002 B1
6377829 Al-Ali Apr 2002 B1
6388240 Schulz et al. May 2002 B2
6397091 Diab et al. May 2002 B2
6411373 Garside et al. Jun 2002 B1
6415167 Blank et al. Jul 2002 B1
6430437 Marro Aug 2002 B1
6430525 Weber et al. Aug 2002 B1
6463311 Diab Oct 2002 B1
6470199 Kopotic et al. Oct 2002 B1
6487429 Hockersmith et al. Nov 2002 B2
6501975 Diab et al. Dec 2002 B2
6505059 Kollias et al. Jan 2003 B1
6515273 Al-Ali Feb 2003 B2
6519487 Parker Feb 2003 B1
6525386 Mills et al. Feb 2003 B1
6526300 Kiani et al. Feb 2003 B1
6534012 Hazen et al. Mar 2003 B1
6541756 Schulz et al. Apr 2003 B2
6542764 Al-Ali et al. Apr 2003 B1
6580086 Schulz et al. Jun 2003 B1
6584336 Ali et al. Jun 2003 B1
6587196 Stippick et al. Jul 2003 B1
6587199 Luu Jul 2003 B1
6595316 Cybulski et al. Jul 2003 B2
6597932 Tian et al. Jul 2003 B2
6597933 Kiani et al. Jul 2003 B2
6606511 Ali et al. Aug 2003 B1
6632181 Flaherty et al. Oct 2003 B2
6635559 Greenwald et al. Oct 2003 B2
6639668 Trepagnier Oct 2003 B1
6640116 Diab Oct 2003 B2
6640117 Makarewicz et al. Oct 2003 B2
6643530 Diab et al. Nov 2003 B2
6650917 Diab et al. Nov 2003 B2
6654624 Diab et al. Nov 2003 B2
6658276 Kiani et al. Dec 2003 B2
6661161 Lanzo et al. Dec 2003 B1
6671531 Al-Ali et al. Dec 2003 B2
6678543 Diab et al. Jan 2004 B2
6684090 Ali et al. Jan 2004 B2
6684091 Parker Jan 2004 B2
6697656 Al-Ali Feb 2004 B1
6697657 Shehada et al. Feb 2004 B1
6697658 Al-Ali Feb 2004 B2
RE38476 Diab et al. Mar 2004 E
6699194 Diab et al. Mar 2004 B1
6714804 Al-Ali et al. Mar 2004 B2
RE38492 Diab et al. Apr 2004 E
6721582 Trepagnier et al. Apr 2004 B2
6721585 Parker Apr 2004 B1
6725075 Al-Ali Apr 2004 B2
6728560 Kollias et al. Apr 2004 B2
6735459 Parker May 2004 B2
6738652 Mattu et al. May 2004 B2
6745060 Diab et al. Jun 2004 B2
6760607 Al-Ali Jul 2004 B2
6770028 Ali et al. Aug 2004 B1
6771994 Kiani et al. Aug 2004 B2
6788965 Ruchti et al. Sep 2004 B2
6792300 Diab et al. Sep 2004 B1
6813511 Diab et al. Nov 2004 B2
6816241 Grubisic Nov 2004 B2
6816741 Diab Nov 2004 B2
6822564 Al-Ali Nov 2004 B2
6826419 Diab et al. Nov 2004 B2
6830711 Mills et al. Dec 2004 B2
6850787 Weber et al. Feb 2005 B2
6850788 Al-Ali Feb 2005 B2
6852083 Caro et al. Feb 2005 B2
6861639 Al-Ali Mar 2005 B2
6876931 Lorenz et al. Apr 2005 B2
6898452 Al-Ali et al. May 2005 B2
6920345 Al-Ali et al. Jul 2005 B2
6931268 Kiani-Azarbayjany et al. Aug 2005 B1
6934570 Kiani et al. Aug 2005 B2
6939305 Flaherty et al. Sep 2005 B2
6943348 Coffin, IV Sep 2005 B1
6950687 Al-Ali Sep 2005 B2
6956649 Acosta et al. Oct 2005 B2
6961598 Diab Nov 2005 B2
6970792 Diab Nov 2005 B1
6979812 Al-Ali Dec 2005 B2
6985764 Mason et al. Jan 2006 B2
6990364 Ruchti et al. Jan 2006 B2
6993371 Kiani et al. Jan 2006 B2
6996427 Ali et al. Feb 2006 B2
6998247 Monfre et al. Feb 2006 B2
6999904 Weber et al. Feb 2006 B2
7003338 Weber et al. Feb 2006 B2
7003339 Diab et al. Feb 2006 B2
7015451 Dalke et al. Mar 2006 B2
7024233 Ali et al. Apr 2006 B2
7027849 Al-Ali Apr 2006 B2
7030749 Al-Ali Apr 2006 B2
7039449 Al-Ali May 2006 B2
7041060 Flaherty et al. May 2006 B2
7044918 Diab May 2006 B2
7048687 Reuss et al. May 2006 B1
7067893 Mills et al. Jun 2006 B2
D526719 Richie, Jr. et al. Aug 2006 S
7096052 Mason et al. Aug 2006 B2
7096054 Abdul-Hafiz et al. Aug 2006 B2
D529616 Deros et al. Oct 2006 S
7132641 Schulz et al. Nov 2006 B2
7133710 Acosta et al. Nov 2006 B2
7142901 Kiani et al. Nov 2006 B2
7149561 Diab Dec 2006 B2
7186966 Al-Ali Mar 2007 B2
7190261 Al-Ali Mar 2007 B2
7215984 Diab May 2007 B2
7215986 Diab May 2007 B2
7221971 Diab May 2007 B2
7225006 Al-Ali et al. May 2007 B2
7225007 Al-Ali May 2007 B2
RE39672 Shehada et al. Jun 2007 E
7239905 Kiani-Azarbayjany et al. Jul 2007 B2
7245953 Parker Jul 2007 B1
7254429 Schurman et al. Aug 2007 B2
7254431 Al-Ali Aug 2007 B2
7254433 Diab et al. Aug 2007 B2
7254434 Schulz et al. Aug 2007 B2
7272425 Al-Ali Sep 2007 B2
7274955 Kiani et al. Sep 2007 B2
D554263 Al-Ali Oct 2007 S
7280858 Al-Ali et al. Oct 2007 B2
7289835 Mansfield et al. Oct 2007 B2
7292883 De Felice et al. Nov 2007 B2
7295866 Al-Ali Nov 2007 B2
7328053 Diab et al. Feb 2008 B1
7332784 Mills et al. Feb 2008 B2
7340287 Mason et al. Mar 2008 B2
7341559 Schulz et al. Mar 2008 B2
7343186 Lamego et al. Mar 2008 B2
D566282 Al-Ali et al. Apr 2008 S
7355512 Al-Ali Apr 2008 B1
7356365 Schurman Apr 2008 B2
7371981 Abdul-Hafiz May 2008 B2
7373193 Al-Ali et al. May 2008 B2
7373194 Weber et al. May 2008 B2
7376453 Diab et al. May 2008 B1
7377794 Al-Ali et al. May 2008 B2
7377899 Weber et al. May 2008 B2
7383070 Diab et al. Jun 2008 B2
7395158 Monfre et al. Jul 2008 B2
7415297 Al-Ali et al. Aug 2008 B2
7428432 Ali et al. Sep 2008 B2
7438683 Al-Ali et al. Oct 2008 B2
7440787 Diab Oct 2008 B2
7454240 Diab et al. Nov 2008 B2
7467002 Weber et al. Dec 2008 B2
7469157 Diab et al. Dec 2008 B2
7471969 Diab et al. Dec 2008 B2
7471971 Diab et al. Dec 2008 B2
7483729 Al-Ali et al. Jan 2009 B2
7483730 Diab et al. Jan 2009 B2
7489958 Diab et al. Feb 2009 B2
7496391 Diab et al. Feb 2009 B2
7496393 Diab et al. Feb 2009 B2
D587657 Al-Ali et al. Mar 2009 S
7499741 Diab et al. Mar 2009 B2
7499835 Weber et al. Mar 2009 B2
7500950 Al-Ali et al. Mar 2009 B2
7509154 Diab et al. Mar 2009 B2
7509494 Al-Ali Mar 2009 B2
7510849 Schurman et al. Mar 2009 B2
7514725 Wojtczuk et al. Apr 2009 B2
7519406 Blank et al. Apr 2009 B2
7526328 Diab et al. Apr 2009 B2
D592507 Wachman et al. May 2009 S
7530942 Diab May 2009 B1
7530949 Al Ali et al. May 2009 B2
7530955 Diab et al. May 2009 B2
7563110 Al-Ali et al. Jul 2009 B2
7593230 Abul-Haj et al. Sep 2009 B2
7596398 Al-Ali et al. Sep 2009 B2
7606608 Blank et al. Oct 2009 B2
7618375 Flaherty Nov 2009 B2
7620674 Ruchti et al. Nov 2009 B2
D606659 Kiani et al. Dec 2009 S
7629039 Eckerbom et al. Dec 2009 B2
7640140 Ruchti et al. Dec 2009 B2
7647083 Al-Ali et al. Jan 2010 B2
D609193 Al-Ali et al. Feb 2010 S
D614305 Al-Ali et al. Apr 2010 S
7697966 Monfre et al. Apr 2010 B2
7698105 Ruchti et al. Apr 2010 B2
RE41317 Parker May 2010 E
RE41333 Blank et al. May 2010 E
7729733 Al-Ali et al. Jun 2010 B2
7734320 Al-Ali Jun 2010 B2
7761127 Al-Ali et al. Jul 2010 B2
7761128 Al-Ali et al. Jul 2010 B2
7764982 Dalke et al. Jul 2010 B2
D621516 Kiani et al. Aug 2010 S
7791155 Diab Sep 2010 B2
7801581 Diab Sep 2010 B2
7822452 Schurman et al. Oct 2010 B2
RE41912 Parker Nov 2010 E
7844313 Kiani et al. Nov 2010 B2
7844314 Al-Ali Nov 2010 B2
7844315 Al-Ali Nov 2010 B2
7865222 Weber et al. Jan 2011 B2
7873497 Weber et al. Jan 2011 B2
7880606 Al-Ali Feb 2011 B2
7880626 Al-Ali et al. Feb 2011 B2
7891355 Al-Ali et al. Feb 2011 B2
7894868 Al-Ali et al. Feb 2011 B2
7899507 Al-Ali et al. Mar 2011 B2
7899518 Trepagnier et al. Mar 2011 B2
7904132 Weber et al. Mar 2011 B2
7909772 Popov et al. Mar 2011 B2
7910875 Al-Ali Mar 2011 B2
7919713 Al-Ali et al. Apr 2011 B2
7937128 Al-Ali May 2011 B2
7937129 Mason et al. May 2011 B2
7937130 Diab et al. May 2011 B2
7941199 Kiani May 2011 B2
7951086 Flaherty et al. May 2011 B2
7957780 Lamego et al. Jun 2011 B2
7962188 Kiani et al. Jun 2011 B2
7962190 Diab et al. Jun 2011 B1
7976472 Kiani Jul 2011 B2
7988637 Diab Aug 2011 B2
7990382 Kiani Aug 2011 B2
7991446 Ali et al. Aug 2011 B2
8000761 Al-Ali Aug 2011 B2
8008088 Bellott et al. Aug 2011 B2
RE42753 Kiani-Azarbayjany et al. Sep 2011 E
8019400 Diab et al. Sep 2011 B2
8028701 Al-Ali et al. Oct 2011 B2
8029765 Bellott et al. Oct 2011 B2
8036727 Schurman et al. Oct 2011 B2
8036728 Diab et al. Oct 2011 B2
8046040 Ali et al. Oct 2011 B2
8046041 Diab et al. Oct 2011 B2
8046042 Diab et al. Oct 2011 B2
8048040 Kiani Nov 2011 B2
8050728 Al-Ali et al. Nov 2011 B2
RE43169 Parker Feb 2012 E
8118620 Al-Ali et al. Feb 2012 B2
8126528 Diab et al. Feb 2012 B2
8128572 Diab et al. Mar 2012 B2
8130105 Al-Ali et al. Mar 2012 B2
8145287 Diab et al. Mar 2012 B2
8150487 Diab et al. Apr 2012 B2
8175672 Parker May 2012 B2
8180420 Diab et al. May 2012 B2
8182443 Kiani May 2012 B1
8185180 Diab et al. May 2012 B2
8190223 Al-Ali et al. May 2012 B2
8190227 Diab et al. May 2012 B2
8203438 Kiani et al. Jun 2012 B2
8203704 Merritt et al. Jun 2012 B2
8204566 Schurman et al. Jun 2012 B2
8219172 Schurman et al. Jul 2012 B2
8224411 Al-Ali et al. Jul 2012 B2
8228181 Al-Ali Jul 2012 B2
8229532 Davis Jul 2012 B2
8229533 Diab et al. Jul 2012 B2
8233955 Al-Ali et al. Jul 2012 B2
8244325 Al-Ali et al. Aug 2012 B2
8255026 Al-Ali Aug 2012 B1
8255027 Al-Ali et al. Aug 2012 B2
8255028 Al-Ali et al. Aug 2012 B2
8260577 Weber et al. Sep 2012 B2
8265723 McHale et al. Sep 2012 B1
8274360 Sampath et al. Sep 2012 B2
8280473 Al-Ali Oct 2012 B2
8301217 Al-Ali et al. Oct 2012 B2
8306596 Schurman et al. Nov 2012 B2
8310336 Muhsin et al. Nov 2012 B2
8315683 Al-Ali et al. Nov 2012 B2
RE43860 Parker Dec 2012 E
8337403 Al-Ali et al. Dec 2012 B2
8346330 Lamego Jan 2013 B2
8353842 Al-Ali et al. Jan 2013 B2
8355766 Macneish, III et al. Jan 2013 B2
8359080 Diab et al. Jan 2013 B2
8364223 Al-Ali et al. Jan 2013 B2
8364226 Diab et al. Jan 2013 B2
8374665 Lamego Feb 2013 B2
8385995 Al-Ali et al. Feb 2013 B2
8385996 Smith et al. Feb 2013 B2
8388353 Kiani et al. Mar 2013 B2
8399822 Al-Ali Mar 2013 B2
8401602 Kiani Mar 2013 B2
8405608 Al-Ali et al. Mar 2013 B2
8414499 Al-Ali et al. Apr 2013 B2
8418524 Al-Ali Apr 2013 B2
8423106 Lamego et al. Apr 2013 B2
8428967 Olsen et al. Apr 2013 B2
8430817 Al-Ali et al. Apr 2013 B1
8437825 Dalvi et al. May 2013 B2
8455290 Siskavich Jun 2013 B2
8457703 Al-Ali Jun 2013 B2
8457707 Kiani Jun 2013 B2
8463349 Diab et al. Jun 2013 B2
8466286 Bellot et al. Jun 2013 B2
8471713 Poeze et al. Jun 2013 B2
8473020 Kiani et al. Jun 2013 B2
8483787 Al-Ali et al. Jul 2013 B2
8489364 Weber et al. Jul 2013 B2
8498684 Weber et al. Jul 2013 B2
8504128 Blank et al. Aug 2013 B2
8509867 Workman et al. Aug 2013 B2
8515509 Bruinsma et al. Aug 2013 B2
8523781 Al-Ali Sep 2013 B2
8529301 Al-Ali et al. Sep 2013 B2
8532727 Ali et al. Sep 2013 B2
8532728 Diab et al. Sep 2013 B2
D692145 Al-Ali et al. Oct 2013 S
8547209 Kiani et al. Oct 2013 B2
8548548 Al-Ali Oct 2013 B2
8548549 Schurman et al. Oct 2013 B2
8548550 Al-Ali et al. Oct 2013 B2
8560032 Al-Ali et al. Oct 2013 B2
8560034 Diab et al. Oct 2013 B1
8570167 Al-Ali Oct 2013 B2
8570503 Vo et al. Oct 2013 B2
8571617 Reichgott et al. Oct 2013 B2
8571618 Lamego et al. Oct 2013 B1
8571619 Al-Ali et al. Oct 2013 B2
8577431 Lamego et al. Nov 2013 B2
8581732 Al-Ali et al. Nov 2013 B2
8584345 Al-Ali et al. Nov 2013 B2
8588880 Abdul-Hafiz et al. Nov 2013 B2
8600467 Al-Ali et al. Dec 2013 B2
8606342 Diab Dec 2013 B2
8626255 Al-Ali et al. Jan 2014 B2
8630691 Lamego et al. Jan 2014 B2
8634889 Al-Ali et al. Jan 2014 B2
8641631 Sierra et al. Feb 2014 B2
8652060 Al-Ali Feb 2014 B2
8663107 Kiani Mar 2014 B2
8666468 Al-Ali Mar 2014 B1
8667967 Al-Ali et al. Mar 2014 B2
8670811 O'Reilly Mar 2014 B2
8670814 Diab et al. Mar 2014 B2
8676286 Weber et al. Mar 2014 B2
8682407 Al-Ali Mar 2014 B2
RE44823 Parker Apr 2014 E
RE44875 Kiani et al. Apr 2014 E
8688183 Bruinsma et al. Apr 2014 B2
8690799 Telfort et al. Apr 2014 B2
8700112 Kiani Apr 2014 B2
8702627 Telfort et al. Apr 2014 B2
8706179 Parker Apr 2014 B2
8712494 MacNeish, III et al. Apr 2014 B1
8715206 Telfort et al. May 2014 B2
8718735 Lamego et al. May 2014 B2
8718737 Diab et al. May 2014 B2
8718738 Blank et al. May 2014 B2
8720249 Al-Ali May 2014 B2
8721541 Al-Ali et al. May 2014 B2
8721542 Al-Ali et al. May 2014 B2
8723677 Kiani May 2014 B1
8740792 Kiani et al. Jun 2014 B1
8754776 Poeze et al. Jun 2014 B2
8755535 Telfort et al. Jun 2014 B2
8755856 Diab et al. Jun 2014 B2
8755872 Marinow Jun 2014 B1
8761850 Lamego Jun 2014 B2
8764671 Kiani Jul 2014 B2
8768423 Shakespeare et al. Jul 2014 B2
8771204 Telfort et al. Jul 2014 B2
8777634 Kiani et al. Jul 2014 B2
8781543 Diab et al. Jul 2014 B2
8781544 Al-Ali et al. Jul 2014 B2
8781549 Al-Ali et al. Jul 2014 B2
8788003 Schurman et al. Jul 2014 B2
8790268 Al-Ali Jul 2014 B2
8801613 Al-Ali et al. Aug 2014 B2
8821397 Al-Ali et al. Sep 2014 B2
8821415 Al-Ali et al. Sep 2014 B2
8830449 Lamego et al. Sep 2014 B1
8831700 Schurman et al. Sep 2014 B2
8840549 Al-Ali et al. Sep 2014 B2
8847740 Kiani et al. Sep 2014 B2
8849365 Smith et al. Sep 2014 B2
8852094 Al-Ali et al. Oct 2014 B2
8852994 Wojtczuk et al. Oct 2014 B2
8868147 Stippick et al. Oct 2014 B2
8868150 Al-Ali et al. Oct 2014 B2
8870792 Al-Ali et al. Oct 2014 B2
8886271 Kiani et al. Nov 2014 B2
8888539 Al-Ali et al. Nov 2014 B2
8888708 Diab et al. Nov 2014 B2
8892180 Weber et al. Nov 2014 B2
8897847 Al-Ali Nov 2014 B2
8909310 Lamego et al. Dec 2014 B2
8911377 Al-Ali Dec 2014 B2
8912909 Al-Ali et al. Dec 2014 B2
8920317 Al-Ali et al. Dec 2014 B2
8921699 Al-Ali et al. Dec 2014 B2
8922382 Al-Ali et al. Dec 2014 B2
8929964 Al-Ali et al. Jan 2015 B2
8942777 Diab et al. Jan 2015 B2
8948834 Diab et al. Feb 2015 B2
8948835 Diab Feb 2015 B2
8965471 Lamego Feb 2015 B2
8983564 Al-Ali Mar 2015 B2
8989831 Al-Ali et al. Mar 2015 B2
8996085 Kiani et al. Mar 2015 B2
8998809 Kiani Apr 2015 B2
9028429 Telfort et al. May 2015 B2
9037207 Al-Ali et al. May 2015 B2
9060721 Reichgott et al. Jun 2015 B2
9060745 Su et al. Jun 2015 B2
9066666 Kiani Jun 2015 B2
9066680 Al-Ali et al. Jun 2015 B1
9072474 Al-Ali et al. Jul 2015 B2
9078560 Schurman et al. Jul 2015 B2
9084569 Weber et al. Jul 2015 B2
9095316 Welch et al. Aug 2015 B2
9106038 Telfort et al. Aug 2015 B2
9107625 Telfort et al. Aug 2015 B2
9107626 Al-Ali et al. Aug 2015 B2
9113831 Al-Ali Aug 2015 B2
9113832 Al-Ali Aug 2015 B2
9119595 Lamego Sep 2015 B2
9131881 Diab et al. Sep 2015 B2
9131882 Al-Ali et al. Sep 2015 B2
9131883 Al-Ali Sep 2015 B2
9131917 Telfort et al. Sep 2015 B2
9138180 Coverston et al. Sep 2015 B1
9138182 Al-Ali et al. Sep 2015 B2
9138192 Weber et al. Sep 2015 B2
9142117 Muhsin et al. Sep 2015 B2
9153112 Kiani et al. Oct 2015 B1
9153121 Kiani et al. Oct 2015 B2
9161696 Al-Ali et al. Oct 2015 B2
9161713 Al-Ali et al. Oct 2015 B2
9167995 Lamego et al. Oct 2015 B2
9176141 Al-Ali et al. Nov 2015 B2
9186102 Bruinsma et al. Nov 2015 B2
9192312 Al-Ali Nov 2015 B2
9192329 Al-Ali Nov 2015 B2
9192351 Telfort et al. Nov 2015 B1
9195385 Al-Ali et al. Nov 2015 B2
9211072 Kiani Dec 2015 B2
9211095 Al-Ali Dec 2015 B1
9218454 Kiani et al. Dec 2015 B2
9226696 Kiani Jan 2016 B2
9241662 Al-Ali et al. Jan 2016 B2
9245668 Vo et al. Jan 2016 B1
9259185 Abdul-Hafiz et al. Feb 2016 B2
9267572 Barker et al. Feb 2016 B2
9277880 Poeze et al. Mar 2016 B2
9289167 Diab et al. Mar 2016 B2
9295421 Kiani et al. Mar 2016 B2
9307928 Al-Ali et al. Apr 2016 B1
9323894 Kiani Apr 2016 B2
D755392 Hwang et al. May 2016 S
9326712 Kiani May 2016 B1
9333316 Kiani May 2016 B2
9339220 Lamego et al. May 2016 B2
9341565 Lamego et al. May 2016 B2
9351673 Diab et al. May 2016 B2
9351675 Al-Ali et al. May 2016 B2
9364181 Kiani et al. Jun 2016 B2
9368671 Wojtczuk et al. Jun 2016 B2
9370325 Al-Ali et al. Jun 2016 B2
9370326 McHale et al. Jun 2016 B2
9370335 Al-Ali et al. Jun 2016 B2
9375185 Ali et al. Jun 2016 B2
9386953 Al-Ali Jul 2016 B2
9386961 Al-Ali et al. Jul 2016 B2
9392945 Al-Ali et al. Jul 2016 B2
9397448 Al-Ali et al. Jul 2016 B2
9408542 Kinast et al. Aug 2016 B1
9436645 Al-Ali et al. Sep 2016 B2
9445759 Lamego et al. Sep 2016 B1
9466919 Kiani et al. Oct 2016 B2
9474474 Lamego et al. Oct 2016 B2
9480422 Al-Ali Nov 2016 B2
9480435 Olsen Nov 2016 B2
9492110 Al-Ali et al. Nov 2016 B2
9510779 Poeze et al. Dec 2016 B2
9517024 Kiani et al. Dec 2016 B2
9532722 Lamego et al. Jan 2017 B2
9538949 Al-Ali et al. Jan 2017 B2
9538980 Telfort et al. Jan 2017 B2
9549696 Lamego et al. Jan 2017 B2
9554737 Schurman et al. Jan 2017 B2
9560996 Kiani Feb 2017 B2
9560998 Al-Ali et al. Feb 2017 B2
9566019 Al-Ali et al. Feb 2017 B2
9579039 Jansen et al. Feb 2017 B2
9591975 Dalvi et al. Mar 2017 B2
9622692 Lamego et al. Apr 2017 B2
9622693 Diab Apr 2017 B2
D788312 Al-Ali et al. May 2017 S
9636055 Al-Ali et al. May 2017 B2
9636056 Al-Ali May 2017 B2
9649054 Lamego et al. May 2017 B2
9662052 Al-Ali et al. May 2017 B2
9668679 Schurman et al. Jun 2017 B2
9668680 Bruinsma et al. Jun 2017 B2
9668703 Al-Ali Jun 2017 B2
9675286 Diab Jun 2017 B2
9687160 Kiani Jun 2017 B2
9693719 Al-Ali et al. Jul 2017 B2
9693737 Al-Ali Jul 2017 B2
9697928 Al-Ali et al. Jul 2017 B2
9717425 Kiani et al. Aug 2017 B2
9717458 Lamego et al. Aug 2017 B2
9724016 Al-Ali et al. Aug 2017 B1
9724024 Al-Ali Aug 2017 B2
9724025 Kiani et al. Aug 2017 B1
9730640 Diab et al. Aug 2017 B2
9743887 Al-Ali et al. Aug 2017 B2
9749232 Sampath et al. Aug 2017 B2
9750442 Olsen Sep 2017 B2
9750443 Smith et al. Sep 2017 B2
9750461 Telfort Sep 2017 B1
9775545 Al-Ali et al. Oct 2017 B2
9775546 Diab et al. Oct 2017 B2
9775570 Al-Ali Oct 2017 B2
9778079 Al-Ali et al. Oct 2017 B1
9782077 Lamego et al. Oct 2017 B2
9782110 Kiani Oct 2017 B2
9787568 Lamego et al. Oct 2017 B2
9788735 Al-Ali Oct 2017 B2
9788768 Al-Ali et al. Oct 2017 B2
9795300 Al-Ali Oct 2017 B2
9795310 Al-Ali Oct 2017 B2
9795358 Telfort et al. Oct 2017 B2
9795739 Al-Ali et al. Oct 2017 B2
9801556 Kiani Oct 2017 B2
9801588 Weber et al. Oct 2017 B2
9808188 Perea et al. Nov 2017 B1
9814418 Weber et al. Nov 2017 B2
9820691 Kiani Nov 2017 B2
9833152 Kiani et al. Dec 2017 B2
9833180 Shakespeare et al. Dec 2017 B2
9839379 Al-Ali et al. Dec 2017 B2
9839381 Weber et al. Dec 2017 B1
9847002 Kiani et al. Dec 2017 B2
9847749 Kiani et al. Dec 2017 B2
9848800 Lee et al. Dec 2017 B1
9848806 Al-Ali et al. Dec 2017 B2
9848807 Lamego Dec 2017 B2
9861298 Eckerbom et al. Jan 2018 B2
9861304 Al-Ali et al. Jan 2018 B2
9861305 Weber et al. Jan 2018 B1
9867578 Al-Ali et al. Jan 2018 B2
9872623 Al-Ali Jan 2018 B2
9876320 Coverston et al. Jan 2018 B2
9877650 Muhsin et al. Jan 2018 B2
9877686 Al-Ali et al. Jan 2018 B2
9891079 Dalvi Feb 2018 B2
9895107 Al-Ali et al. Feb 2018 B2
9913617 Al-Ali et al. Mar 2018 B2
9924893 Schurman et al. Mar 2018 B2
9924897 Abdul-Hafiz Mar 2018 B1
9936917 Poeze et al. Apr 2018 B2
9943269 Muhsin et al. Apr 2018 B2
9949676 Al-Ali Apr 2018 B2
9955937 Telfort May 2018 B2
9965946 Al-Ali May 2018 B2
9980667 Kiani et al. May 2018 B2
D820865 Muhsin et al. Jun 2018 S
9986919 Lamego et al. Jun 2018 B2
9986952 Dalvi et al. Jun 2018 B2
9989560 Poeze et al. Jun 2018 B2
9993207 Al-Ali et al. Jun 2018 B2
10007758 Al-Ali et al. Jun 2018 B2
D822215 Al-Ali et al. Jul 2018 S
D822216 Barker et al. Jul 2018 S
10010276 Al-Ali et al. Jul 2018 B2
10032002 Kiani et al. Jul 2018 B2
10039482 Al-Ali et al. Aug 2018 B2
10052037 Kinast et al. Aug 2018 B2
10058275 Al-Ali et al. Aug 2018 B2
10064562 Al-Ali Sep 2018 B2
10086138 Novak, Jr. Oct 2018 B1
10092200 Al-Ali et al. Oct 2018 B2
10092249 Kiani et al. Oct 2018 B2
10098550 Al-Ali et al. Oct 2018 B2
10098591 Al-Ali et al. Oct 2018 B2
10098610 Al-Ali et al. Oct 2018 B2
10111591 Dyell et al. Oct 2018 B2
D833624 DeJong et al. Nov 2018 S
10123726 Al-Ali et al. Nov 2018 B2
10123729 Dyell et al. Nov 2018 B2
10130289 Al-Ali et al. Nov 2018 B2
10130291 Schurman et al. Nov 2018 B2
D835282 Barker et al. Dec 2018 S
D835283 Barker et al. Dec 2018 S
D835284 Barker et al. Dec 2018 S
D835285 Barker et al. Dec 2018 S
10149616 Al-Ali et al. Dec 2018 B2
10154815 Al-Ali et al. Dec 2018 B2
10159412 Lamego et al. Dec 2018 B2
10188296 Al-Ali et al. Jan 2019 B2
10188331 Al-Ali et al. Jan 2019 B1
10188348 Kiani et al. Jan 2019 B2
RE47218 Ali-Ali Feb 2019 E
RE47244 Kiani et al. Feb 2019 E
RE47249 Kiani et al. Feb 2019 E
10194847 Al-Ali Feb 2019 B2
10194848 Kiani et al. Feb 2019 B1
10201298 Al-Ali et al. Feb 2019 B2
10205272 Kiani et al. Feb 2019 B2
10205291 Scruggs et al. Feb 2019 B2
10213108 Al-Ali Feb 2019 B2
10219706 Al-Ali Mar 2019 B2
10219746 McHale et al. Mar 2019 B2
10226187 Al-Ali et al. Mar 2019 B2
10226576 Kiani Mar 2019 B2
10231657 Al-Ali et al. Mar 2019 B2
10231670 Blank et al. Mar 2019 B2
10231676 Al-Ali et al. Mar 2019 B2
RE47353 Kiani et al. Apr 2019 E
10251585 Al-Ali et al. Apr 2019 B2
10251586 Lamego Apr 2019 B2
10255994 Sampath et al. Apr 2019 B2
10258265 Poeze et al. Apr 2019 B1
10258266 Poeze et al. Apr 2019 B1
10271748 Al-Ali Apr 2019 B2
10278626 Schurman et al. May 2019 B2
10278648 Al-Ali et al. May 2019 B2
10279247 Kiani May 2019 B2
10292628 Poeze et al. May 2019 B1
10292657 Abdul-Hafiz et al. May 2019 B2
10292664 Al-Ali May 2019 B2
10299708 Poeze et al. May 2019 B1
10299709 Perea et al. May 2019 B2
10299720 Brown et al. May 2019 B2
10305775 Lamego et al. May 2019 B2
10307111 Muhsin et al. Jun 2019 B2
10325681 Sampath et al. Jun 2019 B2
10327337 Triman et al. Jun 2019 B2
10327713 Barker et al. Jun 2019 B2
10332630 Al-Ali Jun 2019 B2
10335033 Al-Ali Jul 2019 B2
10335068 Poeze et al. Jul 2019 B2
10335072 Al-Ali et al. Jul 2019 B2
10342470 Al-Ali et al. Jul 2019 B2
10342487 Al-Ali et al. Jul 2019 B2
10342497 Al-Ali et al. Jul 2019 B2
10349895 Telfort et al. Jul 2019 B2
10349898 Al-Ali et al. Jul 2019 B2
10354504 Kiani et al. Jul 2019 B2
10357206 Weber et al. Jul 2019 B2
10357209 Al-Ali Jul 2019 B2
10366787 Sampath et al. Jul 2019 B2
10368787 Reichgott et al. Aug 2019 B2
10376190 Poeze et al. Aug 2019 B1
10376191 Poeze et al. Aug 2019 B1
10383520 Wojtczuk et al. Aug 2019 B2
10383527 Al-Ali Aug 2019 B2
10388120 Muhsin et al. Aug 2019 B2
10398320 Kiani et al. Sep 2019 B2
10405804 Al-Ali Sep 2019 B2
10413666 Al-Ali et al. Sep 2019 B2
10420493 Al-Ali et al. Sep 2019 B2
D864120 Forrest et al. Oct 2019 S
10433776 Al-Ali Oct 2019 B2
10441181 Telfort et al. Oct 2019 B1
10441196 Eckerbom et al. Oct 2019 B2
10448844 Al-Ali et al. Oct 2019 B2
10448871 Al-Ali et al. Oct 2019 B2
10456038 Lamego et al. Oct 2019 B2
10463340 Telfort et al. Nov 2019 B2
10471159 Lapotko et al. Nov 2019 B1
10505311 Al-Ali et al. Dec 2019 B2
10524738 Olsen Jan 2020 B2
10532174 Al-Ali Jan 2020 B2
10537285 Shreim et al. Jan 2020 B2
10542903 Al-Ali et al. Jan 2020 B2
10555678 Dalvi et al. Feb 2020 B2
10568553 O'Neil et al. Feb 2020 B2
RE47882 Al-Ali Mar 2020 E
10608817 Haider et al. Mar 2020 B2
D880477 Forrest et al. Apr 2020 S
10617302 Al-Ali et al. Apr 2020 B2
10617335 Al-Ali et al. Apr 2020 B2
10637181 Al-Ali et al. Apr 2020 B2
D886849 Muhsin et al. Jun 2020 S
D887548 Abdul-Hafiz et al. Jun 2020 S
D887549 Abdul-Hafiz et al. Jun 2020 S
10667764 Ahmed et al. Jun 2020 B2
D890708 Forrest et al. Jul 2020 S
10721785 Al-Ali Jul 2020 B2
10736518 Al-Ali et al. Aug 2020 B2
10750984 Pauley et al. Aug 2020 B2
D897098 Al-Ali Sep 2020 S
10779098 Iswanto et al. Sep 2020 B2
10827961 Iyengar et al. Nov 2020 B1
10828007 Telfort et al. Nov 2020 B1
10832818 Muhsin et al. Nov 2020 B2
10849554 Shreim et al. Dec 2020 B2
10856750 Indorf et al. Dec 2020 B2
D906970 Forrest et al. Jan 2021 S
D908213 Abdul-Hafiz et al. Jan 2021 S
10918281 Al-Ali et al. Feb 2021 B2
10932705 Muhsin et al. Mar 2021 B2
10932729 Kiani et al. Mar 2021 B2
10939878 Kiani et al. Mar 2021 B2
10956950 Al-Ali et al. Mar 2021 B2
D916135 Indorf et al. Apr 2021 S
D917046 Abdul-Hafiz et al. Apr 2021 S
D917550 Indorf et al. Apr 2021 S
D917564 Indorf et al. Apr 2021 S
D917704 Al-Ali et al. Apr 2021 S
10987066 Chandran et al. Apr 2021 B2
10991135 Al-Ali et al. Apr 2021 B2
D919094 Al-Ali et al. May 2021 S
D919100 Al-Ali et al. May 2021 S
11006867 Al-Ali May 2021 B2
D921202 Al-Ali et al. Jun 2021 S
11024064 Muhsin et al. Jun 2021 B2
11026604 Chen et al. Jun 2021 B2
D925597 Chandran et al. Jul 2021 S
D927699 Al-Ali et al. Aug 2021 S
11076777 Lee et al. Aug 2021 B2
11114188 Poeze et al. Sep 2021 B2
D933232 Al-Ali et al. Oct 2021 S
D933233 Al-Ali et al. Oct 2021 S
D933234 Al-Ali et al. Oct 2021 S
11145408 Sampath et al. Oct 2021 B2
11147518 Al-Ali et al. Oct 2021 B1
11185262 Al-Ali et al. Nov 2021 B2
11191484 Kiani et al. Dec 2021 B2
D946596 Ahmed Mar 2022 S
D946597 Ahmed Mar 2022 S
D946598 Ahmed Mar 2022 S
D946617 Ahmed Mar 2022 S
11272839 Al-Ali et al. Mar 2022 B2
11289199 Al-Ali Mar 2022 B2
RE49034 Al-Ali Apr 2022 E
11298021 Muhsin et al. Apr 2022 B2
D950580 Ahmed May 2022 S
D950599 Ahmed May 2022 S
D950738 Al-Ali et al. May 2022 S
D957648 Al-Ali Jul 2022 S
11382567 O'Brien et al. Jul 2022 B2
11389093 Triman et al. Jul 2022 B2
11406286 Al-Ali et al. Aug 2022 B2
11417426 Muhsin et al. Aug 2022 B2
11439329 Lamego Sep 2022 B2
11445948 Scruggs et al. Sep 2022 B2
D965789 Al-Ali et al. Oct 2022 S
D967433 Al-Ali et al. Oct 2022 S
11464410 Muhsin Oct 2022 B2
11504058 Sharma et al. Nov 2022 B1
11504066 Dalvi et al. Nov 2022 B1
D971933 Ahmed Dec 2022 S
D973072 Ahmed Dec 2022 S
D973685 Ahmed Dec 2022 S
D973686 Ahmed Dec 2022 S
D974193 Forrest et al. Jan 2023 S
D979516 Al-Ali et al. Feb 2023 S
D980091 Forrest et al. Mar 2023 S
11596363 Lamego Mar 2023 B2
11627919 Kiani et al. Apr 2023 B2
11637437 Al-Ali et al. Apr 2023 B2
D985498 Al-Ali et al. May 2023 S
11653862 Dalvi et al. May 2023 B2
D989112 Muhsin et al. Jun 2023 S
D989327 Al-Ali et al. Jun 2023 S
11678829 Al-Ali et al. Jun 2023 B2
11679579 Al-Ali Jun 2023 B2
11684296 Vo et al. Jun 2023 B2
11692934 Normand et al. Jul 2023 B2
11701043 Al-Ali et al. Jul 2023 B2
D997365 Hwang Aug 2023 S
11721105 Ranasinghe et al. Aug 2023 B2
11730379 Ahmed et al. Aug 2023 B2
D998625 Indorf et al. Sep 2023 S
D998630 Indorf et al. Sep 2023 S
D998631 Indorf et al. Sep 2023 S
D999244 Indorf et al. Sep 2023 S
D999245 Indorf et al. Sep 2023 S
D999246 Indorf et al. Sep 2023 S
11766198 Pauley et al. Sep 2023 B2
D1000975 Al-Ali et al. Oct 2023 S
11803623 Kiani et al. Oct 2023 B2
11832940 Diab et al. Dec 2023 B2
20010034477 Mansfield et al. Oct 2001 A1
20010039483 Brand et al. Nov 2001 A1
20020010401 Bushmakin et al. Jan 2002 A1
20020058864 Mansfield et al. May 2002 A1
20020133080 Apruzzese et al. Sep 2002 A1
20030013975 Kiani Jan 2003 A1
20030018243 Gerhardt et al. Jan 2003 A1
20030144582 Cohen et al. Jul 2003 A1
20030156288 Barnum et al. Aug 2003 A1
20030212312 Coffin, IV et al. Nov 2003 A1
20040106163 Workman, Jr. et al. Jun 2004 A1
20050055276 Kiani et al. Mar 2005 A1
20050234317 Kiani Oct 2005 A1
20060073719 Kiani Apr 2006 A1
20060161054 Reuss et al. Jul 2006 A1
20060189871 Al-Ali et al. Aug 2006 A1
20070073116 Kiani et al. Mar 2007 A1
20070180140 Welch et al. Aug 2007 A1
20070244377 Cozad et al. Oct 2007 A1
20070282478 Al-Ali et al. Dec 2007 A1
20080064965 Jay et al. Mar 2008 A1
20080094228 Welch et al. Apr 2008 A1
20080103375 Kiani May 2008 A1
20080188760 Al-Ali et al. Aug 2008 A1
20080221418 Al-Ali et al. Sep 2008 A1
20090036759 Ault et al. Feb 2009 A1
20090093687 Telfort et al. Apr 2009 A1
20090095926 MacNeish, III Apr 2009 A1
20090099424 O'Brien et al. Apr 2009 A1
20090247984 Lamego et al. Oct 2009 A1
20090275813 Davis Nov 2009 A1
20090275844 Al-Ali Nov 2009 A1
20100004518 Vo et al. Jan 2010 A1
20100030040 Poeze et al. Feb 2010 A1
20100099964 O'Reilly et al. Apr 2010 A1
20100234718 Sampath et al. Sep 2010 A1
20100270257 Wachman et al. Oct 2010 A1
20110028806 Merritt et al. Feb 2011 A1
20110028809 Goodman Feb 2011 A1
20110040197 Welch et al. Feb 2011 A1
20110082711 Poeze et al. Apr 2011 A1
20110087081 Kiani et al. Apr 2011 A1
20110118561 Tari et al. May 2011 A1
20110125060 Telfort et al. May 2011 A1
20110137297 Kiani et al. Jun 2011 A1
20110172498 Olsen et al. Jul 2011 A1
20110208015 Welch et al. Aug 2011 A1
20110230733 Al-Ali Sep 2011 A1
20120123231 O'Reilly May 2012 A1
20120165629 Merritt et al. Jun 2012 A1
20120209082 Al-Ali Aug 2012 A1
20120209084 Olsen et al. Aug 2012 A1
20120226117 Lamego et al. Sep 2012 A1
20120283524 Kiani et al. Nov 2012 A1
20130023775 Lamego et al. Jan 2013 A1
20130041591 Lamego Feb 2013 A1
20130060147 Welch et al. Mar 2013 A1
20130096405 Garfio Apr 2013 A1
20130096936 Sampath et al. Apr 2013 A1
20130243021 Siskavich Sep 2013 A1
20130253334 Al-Ali et al. Sep 2013 A1
20130296672 O'Neil et al. Nov 2013 A1
20130296713 Al-Ali Nov 2013 A1
20130317322 Andrijauskas Nov 2013 A1
20130324808 Al-Ali et al. Dec 2013 A1
20130331660 Al-Ali et al. Dec 2013 A1
20130345921 Al-Ali et al. Dec 2013 A1
20140012100 Al-Ali et al. Jan 2014 A1
20140051953 Lamego et al. Feb 2014 A1
20140120564 Workman et al. May 2014 A1
20140121482 Merritt et al. May 2014 A1
20140127137 Bellott et al. May 2014 A1
20140163344 Al-Ali Jun 2014 A1
20140166076 Kiani et al. Jun 2014 A1
20140171763 Diab Jun 2014 A1
20140180038 Kiani Jun 2014 A1
20140180154 Sierra et al. Jun 2014 A1
20140180160 Brown et al. Jun 2014 A1
20140187973 Brown et al. Jul 2014 A1
20140213864 Abdul-Hafiz et al. Jul 2014 A1
20140275835 Lamego et al. Sep 2014 A1
20140275871 Lamego et al. Sep 2014 A1
20140275872 Merritt et al. Sep 2014 A1
20140288400 Diab et al. Sep 2014 A1
20140316217 Purdon et al. Oct 2014 A1
20140316218 Purdon et al. Oct 2014 A1
20140316228 Blank et al. Oct 2014 A1
20140323825 Al-Ali et al. Oct 2014 A1
20140323897 Brown et al. Oct 2014 A1
20140323898 Purdon et al. Oct 2014 A1
20140330092 Al-Ali et al. Nov 2014 A1
20140330098 Merritt et al. Nov 2014 A1
20140357966 Al-Ali et al. Dec 2014 A1
20150005600 Blank et al. Jan 2015 A1
20150011907 Purdon et al. Jan 2015 A1
20150032029 Al-Ali et al. Jan 2015 A1
20150038859 Dalvi et al. Feb 2015 A1
20150073241 Lamego Mar 2015 A1
20150080754 Purdon et al. Mar 2015 A1
20150087936 Al-Ali et al. Mar 2015 A1
20150094546 Al-Ali Apr 2015 A1
20150099950 Al-Ali et al. Apr 2015 A1
20150101844 Al-Ali et al. Apr 2015 A1
20150106121 Muhsin et al. Apr 2015 A1
20150112151 Muhsin et al. Apr 2015 A1
20150165312 Kiani Jun 2015 A1
20150196249 Brown et al. Jul 2015 A1
20150216459 Al-Ali et al. Aug 2015 A1
20150238722 Al-Ali Aug 2015 A1
20150245773 Lamego et al. Sep 2015 A1
20150245794 Al-Ali Sep 2015 A1
20150257689 Al-Ali et al. Sep 2015 A1
20150272514 Kiani et al. Oct 2015 A1
20150351697 Weber et al. Dec 2015 A1
20150359429 Al-Ali et al. Dec 2015 A1
20150366507 Blank Dec 2015 A1
20160029932 Al-Ali Feb 2016 A1
20160058347 Reichgott et al. Mar 2016 A1
20160066824 Al-Ali et al. Mar 2016 A1
20160081552 Wojtczuk et al. Mar 2016 A1
20160095543 Telfort et al. Apr 2016 A1
20160095548 Al-Ali et al. Apr 2016 A1
20160103598 Al-Ali et al. Apr 2016 A1
20160166182 Al-Ali et al. Jun 2016 A1
20160166183 Poeze et al. Jun 2016 A1
20160196388 Lamego Jul 2016 A1
20160197436 Barker et al. Jul 2016 A1
20160213281 Eckerbom et al. Jul 2016 A1
20160228043 O'Neil et al. Aug 2016 A1
20160233632 Scruggs et al. Aug 2016 A1
20160234944 Schmidt et al. Aug 2016 A1
20160270735 Diab et al. Sep 2016 A1
20160283665 Sampath et al. Sep 2016 A1
20160287090 Al-Ali et al. Oct 2016 A1
20160287786 Kiani Oct 2016 A1
20160296169 McHale et al. Oct 2016 A1
20160310052 Al-Ali et al. Oct 2016 A1
20160314260 Kiani Oct 2016 A1
20160324488 Olsen Nov 2016 A1
20160327984 Al-Ali et al. Nov 2016 A1
20160331332 Al-Ali Nov 2016 A1
20160367173 Dalvi et al. Dec 2016 A1
20170000394 Al-Ali et al. Jan 2017 A1
20170007134 Al-Ali et al. Jan 2017 A1
20170007198 Al-Ali et al. Jan 2017 A1
20170014083 Diab et al. Jan 2017 A1
20170014084 Al-Ali et al. Jan 2017 A1
20170024748 Haider Jan 2017 A1
20170042488 Muhsin Feb 2017 A1
20170055851 Al-Ali Mar 2017 A1
20170055882 Al-Ali et al. Mar 2017 A1
20170055887 Al-Ali Mar 2017 A1
20170055896 Al-Ali et al. Mar 2017 A1
20170079594 Telfort et al. Mar 2017 A1
20170086723 Al-Ali et al. Mar 2017 A1
20170143281 Olsen May 2017 A1
20170147774 Kiani May 2017 A1
20170156620 Al-Ali et al. Jun 2017 A1
20170173632 Al-Ali Jun 2017 A1
20170187146 Kiani et al. Jun 2017 A1
20170188919 Al-Ali et al. Jul 2017 A1
20170196464 Jansen et al. Jul 2017 A1
20170196470 Lamego et al. Jul 2017 A1
20170224262 Al-Ali Aug 2017 A1
20170228516 Sampath et al. Aug 2017 A1
20170245790 Al-Ali et al. Aug 2017 A1
20170251974 Shreim et al. Sep 2017 A1
20170251975 Shreim et al. Sep 2017 A1
20170258403 Abdul-Hafiz et al. Sep 2017 A1
20170311851 Schurman et al. Nov 2017 A1
20170311891 Kiani et al. Nov 2017 A1
20170325728 Al-Ali et al. Nov 2017 A1
20170332976 Al-Ali et al. Nov 2017 A1
20170340293 Al-Ali et al. Nov 2017 A1
20170360310 Kiani et al. Dec 2017 A1
20170367632 Al-Ali et al. Dec 2017 A1
20180008146 Al-Ali et al. Jan 2018 A1
20180013562 Haider et al. Jan 2018 A1
20180014752 Al-Ali et al. Jan 2018 A1
20180028124 Al-Ali et al. Feb 2018 A1
20180055385 Al-Ali Mar 2018 A1
20180055390 Kiani et al. Mar 2018 A1
20180055430 Diab et al. Mar 2018 A1
20180064381 Shakespeare et al. Mar 2018 A1
20180069776 Lamego et al. Mar 2018 A1
20180070867 Smith et al. Mar 2018 A1
20180082767 Al-Ali et al. Mar 2018 A1
20180085068 Telfort Mar 2018 A1
20180087937 Al-Ali et al. Mar 2018 A1
20180103874 Lee et al. Apr 2018 A1
20180103905 Kiani Apr 2018 A1
20180110478 Al-Ali Apr 2018 A1
20180116575 Perea et al. May 2018 A1
20180125368 Lamego et al. May 2018 A1
20180125430 Al-Ali et al. May 2018 A1
20180125445 Telfort et al. May 2018 A1
20180130325 Kiani et al. May 2018 A1
20180132769 Weber et al. May 2018 A1
20180132770 Lamego May 2018 A1
20180146901 Al-Ali et al. May 2018 A1
20180146902 Kiani et al. May 2018 A1
20180153442 Eckerbom et al. Jun 2018 A1
20180153446 Kiani Jun 2018 A1
20180153447 Al-Ali et al. Jun 2018 A1
20180153448 Weber et al. Jun 2018 A1
20180161499 Al-Ali et al. Jun 2018 A1
20180168491 Al-Ali et al. Jun 2018 A1
20180174679 Sampath et al. Jun 2018 A1
20180174680 Sampath et al. Jun 2018 A1
20180182484 Sampath et al. Jun 2018 A1
20180184917 Kiani Jul 2018 A1
20180192924 Al-Ali Jul 2018 A1
20180192953 Shreim et al. Jul 2018 A1
20180192955 Al-Ali et al. Jul 2018 A1
20180199871 Pauley et al. Jul 2018 A1
20180206795 Al-Ali Jul 2018 A1
20180206815 Telfort Jul 2018 A1
20180213583 Al-Ali Jul 2018 A1
20180214031 Kiani et al. Aug 2018 A1
20180214090 Al-Ali et al. Aug 2018 A1
20180216370 Ishiguro et al. Aug 2018 A1
20180218792 Muhsin et al. Aug 2018 A1
20180225960 Al-Ali et al. Aug 2018 A1
20180238718 Dalvi Aug 2018 A1
20180242853 Al-Ali Aug 2018 A1
20180242921 Muhsin et al. Aug 2018 A1
20180242923 Al-Ali et al. Aug 2018 A1
20180242924 Barker et al. Aug 2018 A1
20180242926 Muhsin et al. Aug 2018 A1
20180247353 Al-Ali et al. Aug 2018 A1
20180247712 Muhsin et al. Aug 2018 A1
20180249933 Schurman et al. Sep 2018 A1
20180253947 Muhsin et al. Sep 2018 A1
20180256087 Al-Ali et al. Sep 2018 A1
20180256113 Weber et al. Sep 2018 A1
20180285094 Housel et al. Oct 2018 A1
20180289325 Poeze et al. Oct 2018 A1
20180289337 Al-Ali et al. Oct 2018 A1
20180296161 Shreim et al. Oct 2018 A1
20180300919 Muhsin et al. Oct 2018 A1
20180310822 Indorf et al. Nov 2018 A1
20180310823 Al-Ali et al. Nov 2018 A1
20180317826 Muhsin Nov 2018 A1
20180317841 Novak, Jr. Nov 2018 A1
20180333055 Lamego et al. Nov 2018 A1
20180333087 Al-Ali Nov 2018 A1
20190000317 Muhsin et al. Jan 2019 A1
20190000362 Kiani et al. Jan 2019 A1
20190015023 Monfre Jan 2019 A1
20190021638 Al-Ali et al. Jan 2019 A1
20190029574 Schurman et al. Jan 2019 A1
20190029578 Al-Ali et al. Jan 2019 A1
20190038143 Al-Ali Feb 2019 A1
20190058280 Al-Ali et al. Feb 2019 A1
20190058281 Al-Ali et al. Feb 2019 A1
20190069813 Al-Ali Mar 2019 A1
20190069814 Al-Ali Mar 2019 A1
20190076028 Al-Ali et al. Mar 2019 A1
20190082979 Al-Ali et al. Mar 2019 A1
20190090748 Al-Ali Mar 2019 A1
20190090760 Kinast et al. Mar 2019 A1
20190090764 Al-Ali Mar 2019 A1
20190104973 Poeze et al. Apr 2019 A1
20190110719 Poeze et al. Apr 2019 A1
20190117070 Muhsin et al. Apr 2019 A1
20190117139 Al-Ali et al. Apr 2019 A1
20190117140 Al-Ali et al. Apr 2019 A1
20190117141 Al-Ali Apr 2019 A1
20190117930 Al-Ali Apr 2019 A1
20190122763 Sampath et al. Apr 2019 A1
20190133525 Al-Ali et al. May 2019 A1
20190142283 Lamego et al. May 2019 A1
20190142344 Telfort et al. May 2019 A1
20190150800 Poeze et al. May 2019 A1
20190150856 Kiani et al. May 2019 A1
20190167161 Al-Ali et al. Jun 2019 A1
20190175019 Al-Ali et al. Jun 2019 A1
20190192076 McHale et al. Jun 2019 A1
20190200941 Chandran et al. Jul 2019 A1
20190201623 Kiani Jul 2019 A1
20190209025 Al-Ali Jul 2019 A1
20190214778 Scruggs et al. Jul 2019 A1
20190216319 Poeze et al. Jul 2019 A1
20190216379 Al-Ali et al. Jul 2019 A1
20190221966 Kiani et al. Jul 2019 A1
20190223804 Blank et al. Jul 2019 A1
20190231199 Al-Ali et al. Aug 2019 A1
20190231241 Al-Ali et al. Aug 2019 A1
20190231270 Abdul-Hafiz et al. Aug 2019 A1
20190239787 Pauley et al. Aug 2019 A1
20190239824 Muhsin et al. Aug 2019 A1
20190254578 Lamego Aug 2019 A1
20190261857 Al-Ali Aug 2019 A1
20190269370 Al-Ali et al. Sep 2019 A1
20190274606 Kiani et al. Sep 2019 A1
20190274627 Al-Ali et al. Sep 2019 A1
20190274635 Al-Ali et al. Sep 2019 A1
20190290136 Dalvi et al. Sep 2019 A1
20190298270 Al-Ali et al. Oct 2019 A1
20190304601 Sampath et al. Oct 2019 A1
20190304605 Al-Ali Oct 2019 A1
20190307377 Perea et al. Oct 2019 A1
20190320906 Olsen Oct 2019 A1
20190374139 Kiani et al. Dec 2019 A1
20190374173 Kiani et al. Dec 2019 A1
20190374713 Kiani et al. Dec 2019 A1
20200021930 Iswanto et al. Jan 2020 A1
20200060869 Telfort et al. Feb 2020 A1
20200111552 Ahmed Apr 2020 A1
20200113435 Muhsin Apr 2020 A1
20200113488 Al-Ali et al. Apr 2020 A1
20200113496 Scruggs et al. Apr 2020 A1
20200113497 Triman et al. Apr 2020 A1
20200113520 Abdul-Hafiz et al. Apr 2020 A1
20200138288 Al-Ali et al. May 2020 A1
20200163597 Dalvi et al. May 2020 A1
20200196877 Vo et al. Jun 2020 A1
20200253474 Muhsin et al. Aug 2020 A1
20200253544 Belur Nagaraj et al. Aug 2020 A1
20200275841 Telfort et al. Sep 2020 A1
20200288983 Telfort et al. Sep 2020 A1
20200321793 Al-Ali et al. Oct 2020 A1
20200329983 Al-Ali et al. Oct 2020 A1
20200329984 Al-Ali et al. Oct 2020 A1
20200329993 Al-Ali et al. Oct 2020 A1
20200330037 Al-Ali et al. Oct 2020 A1
20210022628 Telfort et al. Jan 2021 A1
20210104173 Pauley et al. Apr 2021 A1
20210113121 Diab et al. Apr 2021 A1
20210117525 Kiani et al. Apr 2021 A1
20210118581 Kiani et al. Apr 2021 A1
20210121582 Krishnamani et al. Apr 2021 A1
20210161465 Barker et al. Jun 2021 A1
20210236729 Kiani et al. Aug 2021 A1
20210256267 Ranasinghe et al. Aug 2021 A1
20210256835 Ranasinghe et al. Aug 2021 A1
20210275101 Vo et al. Sep 2021 A1
20210290060 Ahmed Sep 2021 A1
20210290072 Forrest Sep 2021 A1
20210290080 Ahmed Sep 2021 A1
20210290120 Al-Ali Sep 2021 A1
20210290177 Novak, Jr. Sep 2021 A1
20210290184 Ahmed Sep 2021 A1
20210296008 Novak, Jr. Sep 2021 A1
20210330228 Olsen et al. Oct 2021 A1
20210386382 Olsen et al. Dec 2021 A1
20210402110 Pauley et al. Dec 2021 A1
20220026355 Normand et al. Jan 2022 A1
20220039707 Sharma et al. Feb 2022 A1
20220053892 Al-Ali et al. Feb 2022 A1
20220071562 Kiani Mar 2022 A1
20220096603 Kiani et al. Mar 2022 A1
20220151521 Krishnamani et al. May 2022 A1
20220218244 Kiani et al. Jul 2022 A1
20220287574 Telfort et al. Sep 2022 A1
20220296161 Al-Ali et al. Sep 2022 A1
20220361819 Al-Ali et al. Nov 2022 A1
20220379059 Yu et al. Dec 2022 A1
20220392610 Kiani et al. Dec 2022 A1
20230028745 Al-Ali Jan 2023 A1
20230038389 Vo Feb 2023 A1
20230045647 Vo Feb 2023 A1
20230058052 Al-Ali Feb 2023 A1
20230058342 Kiani Feb 2023 A1
20230069789 Koo et al. Mar 2023 A1
20230087671 Telfort et al. Mar 2023 A1
20230110152 Forrest et al. Apr 2023 A1
20230111198 Yu et al. Apr 2023 A1
20230115397 Vo et al. Apr 2023 A1
20230116371 Mills et al. Apr 2023 A1
20230135297 Kiani et al. May 2023 A1
20230138098 Telfort et al. May 2023 A1
20230145155 Krishnamani et al. May 2023 A1
20230147750 Barker et al. May 2023 A1
20230210417 Al-Ali et al. Jul 2023 A1
20230222805 Muhsin et al. Jul 2023 A1
20230222887 Muhsin et al. Jul 2023 A1
20230226331 Kiani et al. Jul 2023 A1
20230284916 Telfort Sep 2023 A1
20230284943 Scruggs et al. Sep 2023 A1
20230301562 Scruggs et al. Sep 2023 A1
20230346993 Kiani et al. Nov 2023 A1
20230368221 Haider Nov 2023 A1
20230371893 Al-Ali et al. Nov 2023 A1
20230389837 Krishnamani et al. Dec 2023 A1
Foreign Referenced Citations (1)
Number Date Country
WO2016036946 Sep 2015 WO
Non-Patent Literature Citations (7)
Entry
US 2022/0192529 A1, 06/2022, Al-Ali et al. (withdrawn)
Audimoolam et al (Predicting Fluid Responsiveness in Acute Liver Failure: A Prospective Study; Feb. 2017 ⋅ vol. 124 ⋅ No. 2 www.anesthesia-analgesia.org). (Year: 2017).
Keller et al (Ability of pleth variability index to detect hemodynamic changes induced by passive leg raising in spontaneously breathing volunteers; Critical Care vol. 12 No 2, 2008). (Year: 2008).
Loupec et al, Pleth variability index predicts fluid responsiveness in critically ill patients, Crit Care Med 2011 vol. 39, No. 2.
Marik et al (Hemodynamic parameters to guide fluid therapy, Annals of Intensive Care 2011, 1:1). (Year: 2011).
Dong et al., “Passive leg raising as an indicator of fluid responsiveness in patients with severe sepsis”, World J Emerg Med vol. 3. No. 3, 2012.
“Pleth Variability Index: A Dynamic Measurement to Help Assess Physiology and Fluid Responsiveness,” 2013 in 12 pages.
Related Publications (1)
Number Date Country
20200138368 A1 May 2020 US
Provisional Applications (1)
Number Date Country
62755802 Nov 2018 US